Report2013

Verein fürKrebsforschung

ArlesheimSwitzerland

Lukas KlinikInstitut Hiscia

The aims of the Society for Cancer Research are

– research in the field of cancer– further development of the medicament

introduced by Rudolf Steiner– further refinement of methods of treatment– providing postgraduate medical training

in those methods.

The registered name of the medicament is Iscador. It is produced from different types of mistletoe (Viscum album).

The Society for Cancer Research does not seek material gain. The charitable nature of the work is recognised by exemption from tax. Streicher & Brotschin Revision und Unternehmensberatung AG in Basel have been appointed auditors.

The Executive Boardof the Society for Cancer Research

Iwer HelwigMichael LorenzMichael Werner

The ideas and opinions expressed in individual articles are those of the authors.

Editing: Corina M. Caminada / Silke Helwig

Print: Schwabe AG, Muttenz

Pictures pp. 9, 42–43: Lukas Klinik archivePictures pp. 46, 59, 62: made available by the writersAll other pictures and postcard: Jürg Buess

Translation: Matthew Barton, GB-Bristol

The Society for Cancer Research

SwitzerlandVerein für KrebsforschungKirschweg 9, CH-4144 ArlesheimPhone +41 61 706 72 72Fax +41 61 706 72 00E-mail: c.brodmann@vfk.chInternet: www.vfk.ch

Donations directly to the Verein für Krebs forschung are accepted as personal or bank cheque. Please mention “Verein für Krebsforschung” on the memo line.

USARudolf Steiner Foundation, Medical Fund1002A O’Reilley Avenue, San Francisco, CA 94129-0915

Donation to the Foundation subject to income tax rebate.

Payment details

To order further issues of our Report or address change please contact:

Verein für KrebsforschungAttn. of Ms. Christine BrodmannKirschweg 9CH-4144 Arlesheimc.brodmann@vfk.ch

Information on Lukas Klinik:www.lukasklinik.chE-mail: kontakt@lukasklinik.chInfoline: +41(0)61 702 09 09Mo 17.00–20.00Wed 08.00–14.00Fri 14.00–17.00

Report 2013

3

Contents

4 Michael Lorenz: Radical changes will unfortunately be necessary

6 Michael Lorenz: Appeal for donations

7 Christoph von Dach: The Lukas Klinik is 50 years old …

9 Silke Helwig: “This is what my life is for“ – anniversary publication to mark Rita Leroi’s 100th birthday

11 Silke Helwig: “… I’m looking forward to us working together on the direction we wish to take over the next 50 years …” Welcome to: Bernd Himstedt-Kämpfer

19 Stephan Baumgartner / Konrad Urech: The 2013 cancer conference in Arlesheim – anthroposophic medical conference on mistletoe therapy

21 Michael Werner: Update of the clinical Iscador study on advanced pancreatic carcinoma

23 Michael Werner: Report on conversion work at Hiscia Institute (Part 2)

26 Corina Caminada: “… how Italian coffee reached Hiscia …” We say farewell to: Donata Bianco

32 Corina Caminada: “I am ending my outward work at the Lukas Klinik, but not my inner connection with it …” We say farewell to: Silke Helwig

42 Jürg Buess/Silke Helwig: Snapshots of the Lukas Klinik – from the early days to now

46 Marcus Reif: A bridge towards general recognition of complementary medicine: The Institute for Clinical Research / Institut für Klinische Forschung, IKF Berlin

52 Colette Pradelle: Anthroposophic medicine in France: a stony path. APMA – the French patient association for anthroposophic medicine in Paris

59 Afsar Imam Syyed: Total wellbeing again: introducing the cancer care foundation in Lahore, Pakistan

63 Farewells

65 Congratulations

66 “Zaubermistel – goldener Zweig“ (“Magic mistletoe – golden bough”) – a new artistic account of mistletoe by Hartmut Ramm and Jürg Buess

68 Corina Caminada: DVD of anthroposophically extended cancer therapy

70 Renatus Ziegler: Documentation of published clinical studies on Iscador

71 Bibliography

4

In last year’s newsletter Herr Helwig made reference to the “2012 adventure” we were

then facing in consequence of changes to statutory healthcare funding in Switzerland (SwissDRG).

At the Lukas Klinik we undertook inten-sive preparations for this change, pursuing a “policy of expansion and differentiation”. In other words we revised the view of ther-apy days, so that they can also be regarded as an out-patient rehabilitation programme. Among other things this necessitated cen-tralized therapy planning.

Following extensive planning, and in line with regulations laid down by the cantonal pharmacy department, our pharmacy underwent a conversion involv-ing modern upgrading and expansion – which we, and above all the patients, are very pleased with.

To meet patients’ needs we have set up a palliative care ward alongside the acute oncology ward. The former is in line with specifications outlined at www.palliativ.ch and was preceded by relevant training and team building.

The palliative care ward was opened in September 2012, and many patients have been able to benefit from this specialized form of high quality nursing.

From October 2012, Benjamin Kohlhase, previously the clinic’s head of ad-ministration, has been appointed to the clinic’s management board. Iwer Hel-wig has withdrawn from this role in order to devote himself fully to his tasks as manager of the Verein für Krebsforschung.

On the acute oncology ward, major changes have arisen due to the fact that, under new DRG regulations, in-patients no longer receive treatment for a pe-riod of 2–3 weeks, but only for between 7 and 10 days. This has led to restruc-turing of therapy procedures in order to maintain the quality of our therapeu-tic provision. Some of the therapies initiated on the ward can then be contin-ued on an out-patient basis.

A further change at the Lukas Klinik to improve patient care is the appointment of Nadja Lichtsteiner as Care Manager. After patients have had their initial con-sultation, she meets them to plan their in-patient stay, and informs them of all further stages in their hospitalization. An assessment is also carried out, and applicable therapies are planned in a way that can best optimize time spent on the ward. The Care Manager also concerns herself with our patients both during and after their stay on the ward. She supports ward physicians with pa-tient coding and healthcare funding issues.

Radical changes will unfortunately be necessary …

5

It was also necessary for us to expand our day-clinic provision, since there is an increasing requirement for intensified Iscador therapy. In combination with infusions, additional treatments such as compresses, massage, eurythmy ther-apy etc. can be given.

Increasing demand has meant that medical consultations have also increased markedly, so that last year it was possible to treat a much greater overall num-ber of patients in the clinic.

Yet despite all efforts it was not possible to ensure that the clinic was always full last year, and this gave rise to a funding deficit. This was also exacerbated by the fact that none of the anthroposophic therapies – intrinsic to our therapy provision – were funded or remunerated.

After evaluation of all options, this pronounced and threatening deficit situ-ation at the Lukas Klinik has led the board of the Verein für Krebsforschung and the directors of the clinic to take a decision to reduce staff numbers at the Lukas Klinik commensurate with actual in-patient numbers. This “rationaliza-tion policy” has already led to early retirements from August 2012, but also to laying off of nursing, artistic therapy and kitchen staff. Further changes in fu-ture will be unavoidable.

In every instance, we wish to ensure that all onward treatment options are maintained, so that the renowned quality of our patient care continues to be available. Plans are underway to secure and improve the Lukas Klinik’s finan-cial situation, and intensive work is being done to realize this.

Michael LorenzSenior physician at the Lukas Klinik and Member of the board of the VfK

6

Dear readers

Following introduction of the Swiss DRG regulations in January 2012, no funding has so far been allocated for any anthroposophic therapies, leav-

ing us with a deficit in the region of 1.5 million Swiss Francs. We wish to con-tinue to offer all our patients the full programme of beneficial therapies in fu-ture. It is likely to take years before funding becomes available from health insurers or the Swiss cantonal authorities, and for this reason we intend to es-tablish an anthroposophic therapy fund so that all therapies can continue to be available to all patients.

We thank you very warmly in advance for your generous support.

Michael LorenzSenior physician at the Lukas Klinik and Member of the board of the VfK

Appeal for donations

7

In other words: for fifty years we have been support-ing people with cancer, and successfully providing mistletoe therapy

We thank all the people who have supported us over the past 50 years. At the same time we send our warm thoughts to all those – in the local re-

gion, in Switzerland and throughout the world – who are affected by cancer directly or indirectly.

The Lukas Klinik Day 2011 was a great success. The Lukas Klinik Day 2013 will take place in September, offering wide-ranging engagement with anthro-posophic oncology to all who are interested. We invite you to attend our offi-cial anniversary celebrations on 13 September.

Three panel discussions at the premises of the Mitte company in Basel, in the summer and autumn, will put these celebrations in context. Here too the em-phasis will be on anthroposophic oncology – from the perspective of patients and physicians, and with a critical examination of Swiss health policy.

We are not just celebrating 50 years of the Lukas Klinik, but also the 100th anniversary of Rita Leroi’s birth. Frau Silke Helwig – a physician who has worked at the Lukas Klinik for many years – is commemorating this pioneer of anthroposophic oncology and founder of the Lukas Klinik in a biography. The book will be launched at a celebration on 11 September, Rita Leroi’s birthday.

Another focus will be linking up with professionals at other oncology centres in the region. This will include the revival of an old tradition: this year, for the first time after many years, a conference on cancer will be held for physi-cians. This will involve sharing our well-founded expertise in anthro posophic oncology and mistletoe therapy with other specialists and developing it fur-ther together.

As a gift to the district of Arlesheim and local people, we have developed the idea of a mistletoe nature trail. On their walk through Arlesheim, visitors will learn interesting facts about mistletoe: its botanical attributes, its processing into the medicine Iscador® and mythological aspects. Donations will be needed to realize this project, and we have posted an appeal on our website, with an account number for donations. Currently we are in the process of discussing possibilities for the nature trail with Arlesheim’s local council. We aim to in-augurate this project at the anniversary celebrations.

This year too, of course, our Lukas Klinik aktuell (newsletter) will be published twice.

The Lukas Klinik is 50 years old …

8

We have developed a special logo and motto to accompany us during this year of celebrations: “Focus on the human being – 50 years of the Lukas Klinik” ex-presses the way we have worked since our founding. We focus on the human being rather than on the disease or external factors. We do everything we can to give comprehensive care to cancer patients and their families, and to keep developing anthroposophic oncology.

The 2013 celebrations at a glance:

15/16 June 2013 Cancer conference 2013, for physicians Ita Wegman Klinik, Arlesheim, “Therapiehaus”

14 August 2013 1st panel discussion: The cancer patient “Unternehmen Mitte”, Basel Talkmaster: Cornelia Kazis (editor Radio SRF 1 and 2)

11 September 2013 Anniversary celebration: 100 years Dr. Rita Leroi, with launch of the book on Rita Leroi

14 September 2013 Lukas Klinik Day 2013 Launch of the mistletoe nature trail project Lukas Klinik/Reformed church community, Arlesheim

19 September 2013 Anniversary celebration: 50 years of the Lukas Klinik Lukas Klinik, Arlesheim

October 2013*) 2nd panel discussion: Health policy “Unternehmen Mitte”, Basel Talkmaster: Cornelia Kazis (editor Radio SRF 1 and 2)

November 2013*) 3rd panel discussion: Anthroposophic oncology today “Unternehmen Mitte”, Basel Talkmaster: Cornelia Kazis (editor Radio SRF 1 and 2)

Please note the dates; you are cordially invited to join the celebrations!

Christoph von Dach RN MScNursing director and member of the clinic’s executive Publicity officer

*) = for the exact dates please see under www.lukasklinik.ch

9

Anniversary publication to mark Rita Leroi’s 100th anniversary

Dr. Rita Leroi made the statement above in relation to her work on Iscador, but it can be understood far

more broadly – as became clear to me in preparing her biographical portrait in celebration of the 100th anniver-sary of her birth, and the 50th birthday of the Lukas Klinik.

Frau Dr. Rita Leroi became director of the Lukas Klinik from the date of its founding, and continued in this role until her death 25 years later.

At the age of 50 a new phase of karmic destiny begins in a person’s life. By then, it is possible that karmic tasks have been fulfilled with the help of the higher hierar-chies (cf. Rudolf Steiner, GA 236, Karmic Relationships, lecture of 29 May 1925). The life challenges approach-ing us from the stream of the past can find their resolu-tion so that new freedom arises to create new destiny – which now comes towards us from the future.

In an individual’s life this transition can often manifest in crisis. Big questions need answering, and a new affirmation and acceptance of what has so far been; at the same time we may need to take leave of, or conclude, our previous ex-periences, and take hold of things in an entirely new way.

It was at this age that Frau Dr. Rita Leroi was asked to become director of the Lu-kas Klinik. This was a major new departure for her, requiring her to move on from her “happiest time as a physician with my own practice”. It also meant carefully cultivating all that had been of value in the past: useful skills for the as yet un-known challenges approaching her from the future. She was fortified and sus-tained by her trust in the wisdom of destiny, and strengthened continually by the direct relationship with anthroposophy she developed right into the most per-sonal aspects of her life. She stayed true to the path she had chosen through the most turbulent times and in the face of all adversity, following a higher aim. Ex-actly a quarter of her life – 25 years – was spent in pursuing these goals.

We can gain a sense of her uncompromising stance in the phrase, “This is what my life is for”, spoken during her endeavours to develop Iscador – synonymous with mistletoe cancer treatment, which Rudolf Steiner characterized as the cen-tral task of anthroposophic medicine.

The Lukas Klinik was to become a “model clinic”, whose essential nature could find its way into the world and thus benefit cancer patients.

“This is what my life is for“ –

10

The numerous discussions I had, and testimonies I heard when preparing my biographical portrait of Rita Leroi to celebrate the 100th anniversary of her birth, and the 50th anniversary of the founding of the Lukas Klinik, showed me the many diverse impulses that people absorbed through her and her work. These impulses – seeds – which took root and developed in the life and work of all these people were exemplary in nature yet took unique form in each instance.

The article from Pakistan which follows is just one small example of this. The biography itself will highlight the further wealth of this diversity, showing that her life is not just a “concluded past” but that her impulse lives on and can be grasped anew to invigorate and shape the future. The interview with Bernd Himstedt offers further signs of this.

For me personally, writing this book was a rich and rewarding experience, and refreshed my sources of inspiration for the future. I am very grateful. I hope that readers will find, similarly, that their “encounter” with Rita Leroi in its pages can inspire and strengthen them.

Silke HelwigMedical director of psycho-oncology, Lukas Klinik

«Es geht um mein Leben» (“This is what my Life is for”)In celebration of the 100th anniversary of Rita Leroi’s birthSilke Helwig (Ed.)To be published by Zbinden Verlag, Basel in September 2013Available in bookshops (ISBN 978-3-85989-449-5)EUR 19.90/CHF 25.80

11

Welcome to: Bernd Himstedt-Kämpfer

On 16 February 2013, Bernd Himstedt-Kämpfer started work as a physician

at the Lukas Klinik, and took over as its medical director from June 2013.

Born in Dusseldorf, in the star sign Cancer, as second child in the family, his Catholic upbringing was influential on him, as were several changes of location in his child-hood – the last of which, when he was 13, saw his arrival in Paderborn, West-falia. He thinks of this as home, and of himself as a Rheinlander.

Mr. Himstedt, what led you to your chosen profession?

After Abitur [school-leaving exams] I felt the world lay open before me and I might do anything. There was no clear priority initially about a choice of career: medicine, philology, law? My grandmother always thought I should study medicine, but I wasn’t so sure. So I began my community service1* with the question of whether I might be suited to working with sick people, and intentionally chose to work in an old people’s home. In working there with extremely needy people I found pleasure and satisfaction. For this reason I did not pursue studies more removed from human concerns, but decided to become a doctor.

Medical studies were very arduous for much of the time because they in-volved so many medical ‘facts’ rather than focusing on the human being him-self. Becoming a physician was a tough obligation. To balance this a little I also studied history and Latin in the first few terms.

After my preclinical studies in Dusseldorf I moved to Berlin: new professional opportunities, the big city, politically exciting times in 1989. Based in Berlin I was able to do something I had set as a goal of my studies – to spend time abroad. Thus I spent the most influential year of my medical studies in north-ern England, close to the Scottish border.

1 * Translator’s note: A compulsory alternative to military service

“… I’m looking forward to us working together on the direction we wish to take over the next 50 years …”

12

Influential?

Yes, in England I found an immediacy of purpose. At that time medical stud-ies in England were more practice-oriented than in Germany, and there was much more contact with patients. In the mornings I was on the ward, in-volved in patient care, and in the afternoons we studied theory. This was in stark contrast to Dusseldorf where we were told: “Well, 50% of you won’t pass this semester anyway.” There was no perception of you as an indi-vidual, whereas in England you had a direct relationship with your teach-ers, patients and your future profession; and lively student life with thea-tre, choir, sport.

Where did you do your clinical traineeship?

Initially in Paderborn, in internal medicine, then later in a hospice in Eng-land. During my preclinical studies I already had contact with people work-ing at the first German palliative care ward in Cologne. In England I could take part in the full life of a hospice. I also worked for two and a half months as a clinical trainee in China. Besides this I spent many semesters as nursing auxiliary in various hospitals in Germany.

Do you have ideals or exemplary figures that you turn to as a physician?

Albert Schweitzer and Frau Dr. Leroi, for instance, are great physicians who impressed me: people who devoted themselves utterly to their profession. The biographies of such people kept me going through hard times in my stud-ies. In actual personal contact I only had a few isolated experiences of col-leagues whom I wished to emulate. But unfortunately no one truly exemplary.

Do you have inner precepts or guiding principles in your work?

Yes, I have experienced powerful things that have remained with me – expe-riences with patients in existential situations. Recalling such things helps me to take difficult decisions.

Professor Mumenthaler once coined the phrase: “The physician begins where the medical scientist stops!”

I relate very much to that: “I must do medicine in order to be a physician.” I have had superiors whose analytic skills greatly impressed me: who could calculate an algorithm in their heads and then make an irreproachable diag-nosis. This was impressive, but it wasn’t for me. That is not my own view of medical practice.

13

Meeting Dr. Rita Leroi one got a tangible sense of the great respect she had for the relationship that develops between the physician and the patient – an interpersonal space; and that she regarded this as an important factor in the therapeutic process …

I repeatedly find this. Particularly in the fields of oncology and palliative med-icine, where people live in existential uncertainty. This is the exciting thing: that alongside professional knowledge, insights and skills, I must always also respond as a human being. Professional competency is the tool, but the re-ally therapeutic aspect begins with the experiences and values with which I meet the patient. Without ignoring the imbalance in the relationship, I can accompany the patient on a part of the journey that he travels; can do so spe-cifically where fundamental principles are concerned, and not just by mull-ing over lab results or handing out yet another pill.

How did you encounter anthroposophic medicine?

This was at an early stage of my studies, through fellow students. At the time I did not understand what anthroposophy was about, and couldn’t get any-where with it. Ultimately it was a biographical story since my husband is a eurythmy therapist. Since we have known each other, I have quite naturally encountered many things. At the same time, in working with people who pre-sent us with questions – “what is the purpose of life, and what happens when we die?” – I have found that the views of orthodox medicine were simply in-adequate. Nor did my Catholicism provide any satisfactory answers. There are rituals that help, it is true, but no real solutions. The anthroposophic im-age of the human being describes something that I have often experienced: that there is part of the human being we can grasp physically and observe with our corporeal senses, but that there is another aspect that goes beyond this, is independent or free of the body and not a mere function of it. Rudolf Steiner says: “The spirit does not become sick.” This is wonderful and at the same time an enormous challenge in daily work. How do I support and ac-company this human essence? What may I do, and what must I do? How do I ease physical complaints in a way that truly helps a person rather than just making the situation more bearable for bystanders?

I have often heard people saying, shortly before their death: “I have never felt so healthy as I do now!” That is a different concept of healing, isn’t it?

A different concept of healing, but also the experience of a deeper reality. Working with a person at the end of his life is a joyful thing if the patient can express such feelings. Of course there is always a farewell involved, and grief. But if acceptance is possible by the patient and relatives, a great deal of peace arises. You enter the room and think: “My God, I want to stay here, it is so beautiful.” Cicely Saunders founded the first modern hospice in Eng-

14

land and laid the basis for our current view of hospice work and palliative medicine. She once put it like this: ‘There are times when the interests of health are served by dying.”

The Saunders model?

Yes, she recognized that a great need exists. She saw the needs and afflic-tions of gravely ill people. She wanted to help and simply started doing so. She worked, trained herself – she was a nurse, social worker and physi-cian – and looked for what she needed. She did not wait for circumstances to change but worked until she had achieved her goal. And that is already exemplary.

Exemplary in the sense of: ‘I relate to this, it elicits my inner response.” In the same way that anthroposophy becomes comprehensible in practical ex-perience?

Experience of a deeper reality does not just arise in people who have that kind of worldview. I have often found that people with very different attitudes to spirituality, quite independently of each other, feel there is still something that needs doing for someone who has died. One person prays, another be-comes quiet and reflective, a third opens the window – each as he feels the need. But they are united by a perception that more exists than the lifeless body lying there.

Something diffuse that is perceived. And through anthroposophy we can give it a name …

Yes, precisely. These experiences led me to engage with anthroposophic med-icine. In Berlin I attended the medical seminar and started to use anthropo-sophic methods and medicines in my daily work.

What support do you draw on in your work?

My family firstly. And experiences with patients. If someone goes toward death in a healthy way or in the way he faces a life-threatening illness, or passes through a huge process of development – I can become very still, and feel wonder. When I witness this, mundane life falls away and I draw strength from the experience. I also do so in spiritual work, and prayer. And another source of strength – though one that is sadly rather in abeyance at present – is music and playing the piano.

15

Can you describe your professional connection with palliative medicine, and how this has developed?

I remember in my schooldays, already, that I was fascinated by discussions about euthanasia and the care of severely ill patients. Until my medical stud-ies, and during them too, there was a time when I gathered a great many dif-ferent impressions – years when I absorbed many ideas, for instance when I worked with residents in the old people’s home during my community ser-vice. During my studies I focused intensively on geriatrics, the care of the elderly. In its origins, geriatrics was exclusively concerned with patients’ po-tential for rehabilitation, but my question was this: “What about those who really have no such potential?” That’s why I couldn’t stay in this field. In my first period as intern I did surgery, enjoyed this hands-on work, and today still do small-scale surgical interventions. Then followed a period as locum in general practices, where I learned a great deal about relating to parents and medical issues. Yet I noticed that none of this really spoke to me. So then came the question of what to do next, and I once again thought of pal-liative medicine. Home Care Berlin was looking for new staff, and I found my place there.

Home Care?

… a charitable association, attached to oncology practices in Berlin, a pi-lot project. It was based on insight into the fact that it was not enough just to tell a patient that chemotherapy could do no more for him and he must now fend for himself. The impulse developed from this principle. We cared for people with cancer at home during the last period of their lives, trying to give them as good a quality of life as possible and make it possible for them to die at home. We learned on the job, since there was no actual training for this. But when you’re available seven days a week, 24 hours a day, you learn very quickly. And there were experienced colleagues who offered patients a great deal of support – we were a good team.

After two and a half years I realized that I could not imagine working like this for the next 30 years. It was pretty draining. With a heavy heart I decided to train as a specialist.

Where did this lead you next?

To Brandenburg in Germany: a challenge, since people there had a very dif-ferent social outlook from me with my Catholic perspective, and their way of dealing with dying and death was very alien to me. In the city of Branden-burg I did my training in the different fields of internal medicine, to become an internist.

16

But I realized that to properly care for a patient in palliative medicine it is important to know his past – not just as a case history but in direct experi-ence of what he brings with him. I therefore found an oncology department in a specialist hospital in Potsdam. We cared for patients with severe hae-matological and oncological disorders, undertook stem cell transplants, and I had formative experiences that taught me about the possibilities and prob-lems of high-tech medicine in oncology. I took my exams to become a spe-cialist in haematology and oncology.

Parallel to this we developed a palliative ward concept, and launched this in practice. We established in-house palliative medicine and ran courses for nurses, physicians and volunteers. I also qualified, additionally, in “pallia-tive medicine for doctors”, which allowed me to practise in Switzerland. We brought something to life that did not exist in the region previously. In my overall responsibility as assistant medical director I was also involved with in-patient and out-patient care of oncology patients.

And what brought you here to the Lukas Klinik?

That was a telling thing. My husband had decided to stop doing eurythmy therapy after 17 years. We trusted that life would show us our next step. Shortly after he had stopped, I received an enquiry from a eurythmy thera-pist about a position at the Lukas Klinik – asking me if I would be interested in working there. Thinking about this, I realized that this was exactly the right thing for me: to work with a comprehensive image of the human being in oncology and palliative medicine. Here, it seemed, I could elaborate what I had so far learned of anthroposophy, and take further steps in my own devel-opment. It was time for a change for the whole family: my husband and our two boys. I also sensed that in Postdam, after four years, the situation had reached a stage when someone else could take it over. And so we were free to take this step: it felt completely right.

Right?

When I visited the clinic for the first time I already thought: this is good, it feels right. It did not seem at all unfamiliar, but rather the opposite.

… this experience of first encounter is fascinating …

… it has a great deal to do with the outlook that lives here. The way of ap-proaching patients. It was very striking to experience this.

17

When you think of working here, what do you look forward to?

I am looking forward to working with the people at the Lukas Klinik, work-ing together on the direction we wish to take over the next 50 years … It’s a brilliant thing for me that the clinic has existed for 50 years, and we must now ask how things should develop in future! Many biographical threads are now coming together for me personally. I can bring a range of knowledge, insights and experiences to this work, and collaborate with others to create a new quality, a new perspective.

… A new challenge in your life …

… which I experience as being of a whole new dimension. Previously when I changed jobs I had very specific ideas such as training in a new special-ism, focusing on oncology, starting the palliative ward. But now it seems that my biographical task is to introduce, in one particular place, all that I have so far learned.

As preparation …

It seems very much like it to me at present. In Postdam in recent years, for instance, I also had to concern myself with the finances of the haematology and oncology clinic. This didn’t come naturally to me – it was a fairly ardu-ous duty. But I worked my way into it and gained a basic understanding of the fixed rate-per-case system. I can handle these figures and understand what is or isn’t covered by them. As far as circumstances in Switzerland are con-cerned, I can now say that all this had a purpose.

… So what picture do you now have before you?

One with many different aspects: a vibrant Lukas Klinik that is open to the outside world. Where people work hard to understand what anthroposoph-ically-oriented oncology is. Steiner says, after all, that the anthroposophic physician must first have an orthodox medical training, and then understand what is involved in extending this into anthroposophic medicine, and put-ting this into practice. The question therefore is: What does it mean to unite both of these in a real sense? What is the fitting contemporary form for it?

The care of people with cancer starts with the initial diagnosis, and progresses to a physical cure and after-care, or alternatively to death. It is our task to ac-company them on this journey. The outer form we find for this is important but nevertheless secondary.

18

The Lukas Klinik has an international reputation and at the same time re-quires strong regional stability – in the same way that in-patient and out-pa-tient care are interdependent. It will be a matter of painting this complex pic-ture together and repeatedly enlivening it with new colours.

I and all the staff wish you the very best in this undertaking, for the benefit of the Lukas Klinik itself, and thus primarily for the welfare of its patients.

Interview with Bernd Himstedt-Kämpfer by Silke Helwig

19

Anthroposophic medical conference on mistletoe therapy

Treatment with mistletoe extracts (Iscador) is one of the most common complementary medical procedures requested by cancer patients. It has

been used for over 90 years now, and has proven its worth in a great many cases. At the same time this treatment is continually being developed and im-proved. This involves, firstly, research and development on the Iscador prep-aration itself, as carried out on an ongoing basis at Hiscia Institute since its founding in 1949; and secondly, engagement with the many questions that arise in relation to use of Iscador in daily clinical practice – such as new applications, optimum doses or the choice of host trees depending on indi-cation.

Professional dialogue between scientists and physicians working in a particu-lar field of medicine is essential for resolving open questions. In the field of mistletoe therapy there are regular conferences on a range of issues. In recent years, within academic science in particular, there has been increased debate about the foundations and applications of mistletoe therapy. Thus mistletoe has not just been a theme at conferences on complementary medicine – for instance the annual European Conference for Integrative Medicine – but also at conventional conferences on cancer therapy such as the 2012 ESMO (Eu-ropean Society of Medical Oncology) in Vienna.

In recent years however, there has also been an increasingly insistent need amongst many practising physicians for a regular anthroposophic study con-ference focusing on exchange of clinical experiences and the origins of mis-tletoe therapy. After repeated enquiries, the Society for Cancer Research has decided to organize such a conference for doctors in June 2013. We are pleased to say that this will take place at the Ita Wegman Clinic therapy cen-tre, so that the conference location itself, as well as its content, will highlight a connection with anthroposophic medicine’s founding impulses and with Ita Wegman. This represents the renewal of an old tradition, since the Soci-ety for Cancer Research, which Ita Wegman cofounded in 1935, formerly held a medical conference here for decades under the auspices of Dr. Alex-andre Leroi and later Dr. Rita Leroi, as the focus of clinical dialogue on mis-tletoe therapy.

To be able to keep the conference to a manageable scale and cater for the needs and wishes of participants, the 2013 conference is primarily planned for anthroposophic physicians and clinics in Switzerland. Alongside keynote papers on the origins of mistletoe therapy, four main themes are to be accen-tuated: mistletoe or Iscador therapy of pancreatic carcinoma, body temper-ature and cancer, anthroposophic palliative medicine, and new pharmaceu-tical developments at Hiscia Institute. With this conference we hope to rec-

The 2013 cancer conference in Arlesheim

20

reate a common forum for regular clinical dialogue and for the development of anthroposophic mistletoe therapy, broadening its range and significance also beyond the borders of Switzerland.

For the conference organization committee: Dr. Konrad Urech, Dr. Stephan Baumgartner

Cancer Conference 201315/16 Junein Arlesheim/CH

Programme see www.vfk.ch/information/krebstagung (in German only)

21

In what has now become almost something of a tra-dition, I wish to report in this newsletter on our cur-

rently most striking and interesting clinical study on Iscador, and update our readers on this increasingly important aspect of our work: research into Iscador’s clinical efficacy.

Some years back we initiated a prospective ran-domized Phase III study in Belgrade (Serbia) which is now close to completion. In this study, patients with locally advanced or metastizing pancreatic car-cinoma were treated for a 12-month period.

Half of the patients received Best Supportive Care (BSC) for treatment of acute, tumour-related symp-toms, while the other half received subcutaneous in-jections of Iscador Qu Special three times weekly.

The primary study goal was focused on overall sur-vival (OS), while the secondary goal was patients’ quality of life, as measured in the EORTC-QLC-C30 questionnaire sheet.

Evaluation of the planned interim analysis after treat-ment of 220 patients out of an original total of 400, produced a statistically highly significant and clinically relevant result. Acting on the advice of a committee of experts, recruitment of further patients was therefore halted early due to ‘proven efficacy’.

These striking findings can now be published since they have, in the meantime, been presented at the following two specialist medical conferences:

ECIM European Congress for Integrative Medicine in Florence, 21/22.9.2012

Galun D et al., European Journal of Integrative Medicine 4, suppl.: OP-007, 11-12 (2012)

and

ESMO European Society of Medical Oncology in Vienna, 28.9.-2.10. 2012

Galun D et al., Annals of Oncology 23, suppl.9:712 (2012).

Following evaluation of the study data, the primary study goal of overall sur-vival was found to give a median survival time of 4.8 months in the Isca-dor group as compared to 2.7 months in the control group (diagram 1). Just 2–3 months after start of Iscador treatment, we ascertained a marked benefit

Update of the clinical Iscador study on advanced pancreatic carcinoma

22

in this group compared to the control; likewise striking is the number of ‘long-term survivors’: 17 out of 110 patients in the Iscador group (15.5%) compared to only 2 out of 110 (1.8%).

Documentation of quality of life revealed equally striking benefits for the Isca-dor group. 13 out of 15 parameters surveyed were significantly improved to a clinically relevant degree.

Quality of life improved in the Iscador group during the course of treatment, whereas it increasingly deteriorated in the control group. A persuasive indica-tion of this became apparent in connection with recording of patients’ body-weight (diagram 3). Average weight of control patients diminished worryingly at each consultation, whereas it was found to rise slightly after start of mistle-toe therapy in the Iscador group.

In a special report on this study, the Austrian medical periodical “Ärzte Woche” recommends “Iscador therapy as an effective life-prolonging option with si-multaneous improvement of quality of life for patients with locally advanced or metastizing pancreatic carcinoma”.

It is to be hoped that these convincing study results will help consolidate and broaden acceptance of our mistletoe preparation Iscador.

The next stage of our clinical research programme is to prepare a study aimed at showing that patients with pancreatic carcinoma, treated with the standard therapies in Central Europe (Gemcitabine, Folforinox …) can similarly bene-fit through extension of survival times and improvement in quality of life from supplementary Iscador treatment. We hope to be able to provide positive re-ports on this in future.

Dr. rer. nat. Michael WernerDirector of the Hiscia Institute

23

The new ampoule-filling department

A year ago – shortly before the start of construction work for the acute ward – we published a report on the conversion work planned at Hiscia in 2012.

One important reason for this huge undertaking was that our ampoule-filling department had grown ‘antiquated’, requiring thorough renovation and par-tial reconstruction. After weighing up the pros and cons we decided to build entirely new additional premises for ampoule-filling and the preparatory work connected with, this on the flat roof of Hiscia Institute’s west wing. This would allow us to go on producing Iscador ampoules – needed by Weleda Switzer-land – in the old premises up to the very last moment.

Now, 12 months later, after an unsettled but always interesting and fairly un-problematic conversion phase, we can say that we have done it! Our new ampoule-filling department is up and running, and the extra packaging unit, which will only need to become operational at a later stage, is underway and on schedule.

Inspection by the RHINW supervisory authority (regional medicines inspec-torate of north-west Switzerland), which takes place roughly every two years, was postponed to 4/5 March 2013 due to these conversion works. This impor-tant inspection of the new production premises and scrutiny of production sequences has in the meantime been carried out and, save for a few small

Report on conversion work at Hiscia Institute (Part 2)

Picture 1

24

inadequacies that always come to light in such inspections, has been passed as fundamentally sound.

From a purely external point of view, our Hiscia Institute has undergone very noticeable and – in our view – very favourable changes. The adjoining pho-tos show the west wing of Hiscia Institute before (picture 1) and after (pic-ture 2) conversion. The room for ampoule-filling preparation is located in the upper right-hand part of the new building, with the new service autoclaves (picture 3) and a rinsing machine for cleanroom equipment (picture 4). In the middle of the new upper storey is the actual ampoule-filling section with the new, larger and more efficient ampoule-filling machine (pictures 5 and 6).

In the left-hand part of the new building are extensive technical facilities for cleanroom ventilation of the whole production area: an impressively com-plex and elaborate system of ventilators, filters, coolers, heat exchangers and associated circuitry for controlling and monitoring sterile airflow. All this is required today for operating aseptic filling of sterile medicines. These very strict conditions are connected with the temperature-sensitive contents of our Iscador, which cannot be autoclaved after ampoule-filling.

In future in these new premises we will primarily produce the smaller ranges and batches from the extensive range of Iscador ampoules, along with a fur-ther series of proven magistral formulae for the Lukas Klinik and the Weg-man Klinik, which could otherwise no longer be produced due to the lim-ited quantities required, and would therefore no longer be available to phy-sicians and patients.

Picture 2

25

Given the current situation in which Weleda cancelled its basic agreement with the Verein für Krebsforschung in January of this year, we will face a quite new and previously unknown situation after the notice period of two years. We are therefore very pleased that the new ampoule-filling and packaging departments will enable us to ensure that Iscador patients continue to receive their helpful, healing medication in future, thus retaining the beneficial di-versity of this tried and tested anthroposophic medicine.

Dr. rer. nat. Michael WernerDirector of the Hiscia Institute

Picture 3 Picture 4

Picture 5 Picture 6

26

We say farewell to: Donata Bianco

From 1 August 1972 to the end of August 2012, Donata Bianco worked at Hiscia’s Iscador mi-

crobiology/manufacturing department. She lives with her family in Dornach SO, and since her re-tirement also in Italy. We asked her for an inter-view about her recollections of working here …

Dear Donata, you arrived at Hiscia on 1 August 1972. Please tell us how you found your way here.

Yes, it was 1 August. I did know that this was a national holiday in Switzerland, but Herr Strom (the director of the Society of Cancer Research at the time) told me I should begin that day. I started in the laundry of Merkur staff house, and worked there on 1 August quite alone with the lady in charge, Frau Fischer. The next day other colleagues joined me.

Prior to this I had worked in a pharmacy for three years, and applied initially for work in Weleda. My husband was already in Switzerland. Weleda told me that Hiscia was looking for staff. So I came here and introduced myself. At the time they were looking for someone and I started in the microbiology depart-ment. I didn’t actually want to come to Switzerland; at the time I wept about it. And now I weep because I’m leaving!

Does this mean that you worked the whole forty years in Hiscia Institute’s microbiology department?

Yes, but I always worked in the production department too, filling ampoules, labelling. But back then it was quite different from today.

We can see that from the few old photos we still have. What do you consider to be the biggest changes compared to the old days?

Hard to say. In those days we did everything ourselves. For instance, we car-ried out the blood crystallization imaging and the capillary dynamolysis – which Frau Scherr does now – and the drying tests and also sterilization tests by hand. There were no machines to do this. It was the pioneer phase – eve-

“... how Italian coffee reached Hiscia …”

27

ryone did everything, turned their hand to whatever needed doing. In those days we did not produce such large quantities of Iscador either. We ampouled about 3 litres a day. We couldn’t do more than that because it was all done by hand. Herr Hennink developed a machine for filling the ampoules, and instead of labels we started stamping every single ampoule by hand. Later we had a somewhat more up-to-date machine that could fill 10 ampoules at once. But in those days we also lined the bottles containing Iscador concentrate, and the ampoules too, with beeswax. As yet there was no ‘use by’ date.

(Note: Suggestions for lining glass bottles and ampoules originate with R. Steiner, and aim to protect the organic mistletoe juice from coming into con-tact with the mineral substance of glass)

This must have been a huge amount of work; how was it actually done?

First the beeswax had to be prepared: it was filtered, sterilized in the drying cabinet: this was done a week before use. The insides of the glass containers were rinsed with acid so that the wax would adhere to the glass. Then on the day itself the wax was heated to 80 °C to render it fluid. We poured wax into the bottles then kept gently rotating each one to distribute the wax evenly. Wax was also placed in the neck of the bottle before it was sealed – which had to stay closed, but not too firmly because otherwise you could not get the top off again. If the preparatory rinsing with acid was not done properly, the wax did not adhere and the whole thing had to be done again. So we had to work very carefully and it took much effort. In this way we washed about 20 bottles a day.

Because each step was so laborious, we could always only produce one type of Iscador at a time. For instance, one day we would just make ampoules for Weleda, and the next day magistral preparations for the Lukas Klinik. Today that would no longer be conceivable of course. New staff members often joined us, stayed for three months and then left again – usually, in those days, to work for Ciba-Geigy or Sandoz. But I liked doing this work – it was fun despite everything, for it was varied and diverse. And we were involved in the whole production sequence.

You mentioned earlier that back then Hiscia was like a big family; and I know that you used to sing while working. Can you say any more about this?

Yes, we sang, especially while selecting plants but also during the juice mix-ing process. In the early days, we loaded the plant juices for mixing on a little cart, along with the empty bottles and everything we needed. We pulled the cart to the machine. The rotation process was done morning and evening, and beforehand we had to clean everything until it sparkled. For us it was a festival that we always looked forward to. For example, at the St. John’s rotation (June), people from the Lukas Klinik brought us ice cream at the end of the work, and everyone sat down together and enjoyed it.

28

In those days has the mixing process also been accompanied with contem-plative texts?

We did that during mistletoe selection. We all sat in the selection room the whole day and sorted the plants and the berries. Frau Dr. Leroi frequently joined us. The days for this were carefully chosen by moon constellation. The plants were also sorted at particular times of day. Then, before work started, and also before the mixing machine was set in motion, Frau Leroi read a text by R. Steiner. During the mixing process it was like being in church, a very special mood. All the production department staff was always present and helped. Af-ter work, everything was cleaned again, all the materials and the fresh Iscador loaded on the hand-cart again, and we took it all back to Hiscia, cleared up and then went home. Sometimes I even arrived at Hiscia at three in the morn-ing to prepare Iscador.

Was that something to do with the right planetary constellation?

Yes, exactly: this was required in those days. I arrived at Hiscia at three in the morning and started straight away with selection and sorting. This would take until about 10 a.m., when we had a coffee break. Then we carried on sorting – depending on the day and the constellation –from about three in the after-noon, sometimes continuing until ten o’clock at night.

Both summer and winter?

Certainly, yes, it was exactly the same in winter, depending on the moon po-sition. The rotation always took place at Easter and in September. This has remained so to this day. But it was a lovely time, like a festival celebration! But as I said, the quantities of Iscador were much smaller in those days. We might have spun 6 litres altogether, whereas today we make 80 or 100 litres per rotation.

It was really fine and I loved it. We sang as we sorted the plants, too. But the best of all was the evening afterwards when we all sat together and celebrated and sang. On one occasion, Dr. Hoffmann (Dr. Leroi’s successor) was even pre-sent and cooked spaghetti for us at nine in the evening.

Where did you cook and take breaks in those days? We didn’t have a kitchen yet.

That’s true, and we didn’t have coffee either back then; instead we always fetched fresh milk from the Lukas Klinik in a milk can, and crispbread. We used to heat the milk up on the gas stove. In those days, Frau Haller, the lady at re-ception, and later it was Frau Brodmann, rang the gong three times at 9 a.m. to tell everyone it was time for the break. And so, no one needed to keep an eye

29

on the clock. We all went and got our cups, fetched the milk and crispbread, and usually had our break in the plant lab when we were sorting plants. Then each person would talk about what they’d done the evening before. The work was hard, but it was a lovely era. I’d love to go back to those times. Everything was jollier and more cheerful. We laughed a lot, knew each other well person-ally. In the summer, we used to go out into the garden for our break. Clothing regulations mean that we can’t do that any more. In those days we just wore our ordinary clothes.

Donata, there’s another basic question I’d like to ask you: when you came to work at Hiscia, did you know anything at all yet about anthroposophy?

No, but I was interested. You can say that I grew into anthroposophy through working here. I was very young, and open for it. But it was really only through my two daughters-in-law that I became very conversant with it: they taught me a lot about it. They sent their own children to the Waldorf School and know many parents who were brought up in anthroposophical homes. I must say that I have always been very impressed with the human qualities anthroposophy gives interpersonal relations. Though here too, of course, as everywhere else, there were sometimes problems between people.

Could we talk briefly about Frau Dr. Rita Leroi? Her 100th birthday will be celebrated in 2013 of course. She was chief physician at the Lukas Klinik and managing director of the Hiscia Institute. After the death of her husband, she continued to run the Verein für Krebsforschung in a strict and rigorous way. But she was also known for placing a lot of importance on human qualities. She asked members of staff how they were, how their family was, took an in-terest in people. Is that how you remember her?

Yes, but she wasn’t always so humane. Elisabetta had been working in the pro-duction department: she was young and had been working a lot of overtime hours and naturally wanted to have these recorded and remunerated; but she wasn’t allowed to. She was told that we work here for sick people, we are here to serve them, and this isn’t to be paid for on an overtime basis. She went to Frau Leroi to complain about this, but it was no good. Frau Leroi told her that if patients need her she goes to see them, no matter at what time of day, and that she doesn’t get paid extra for doing this. That’s how it was in those days.

As you know, Iscador manufacture is the pillar on which our enterprise is founded. It embodies our work, and is dispatched throughout the world. For over 40 years, you have made a decisive contribution to this work, as “pro-duction mother” one might say. And it is indisputable that the thoughts and feelings which accompany this work have an enormous effect on the prep-aration itself. This is known today, also beyond the anthroposophic context.

30

I believe this, too. Things used to be run very strictly by Frau Leroi, and Frau Gröngraft who managed the production department. But when Herr Buess be-came production manager (from 1982), we had someone very kind, nice and understanding – a warm human being. I think this is also important.

Dear Donata, we haven’t yet spoken about the cancer conference that used to be held here at Hiscia every year.

Oh yes, that was a special event: it ran through the weekend, usually from Fri-day evening to Sunday afternoon. That was always a festive occasion for us. Flowers were brought in, and a large basket of apples. Then we sat down and polished the apples with a cloth until they shone. In another basket we pre-pared sweets, and on the morning of the conference, we arrived at Hiscia and made fresh coffee.

The doctors who took part – where did they come from? Just from Switzer-land?

They came from everywhere: Germany, Italy, the whole of Europe. The cancer conference itself took place for many years in the Ita Wegman Clinic’s historic wooden house, right next to Hiscia. We ladies of the production department wore aprons and served the guests, like waitresses. We enjoyed this very much.

Finally, please tell us the secret of how Italian coffee reached Hiscia …

When there was still milk and crispbread, we in the production department each used to bring our own thermos flask with coffee, until one day we had the idea of making coffee together here. That was still filter coffee until later we brought mocha coffee along. And when we were making our coffee, sud-denly everyone else wanted it, too. This carried on until you introduced the cof-fee machine. Previously we in the production department had the first break, and made our coffee; and the second break group drank the rest of it – un-til we started making coffee for everyone. We used to buy all the things our-selves, and gradually the others started to make a small contribution. But then people would keep an eye on how much jam, say, each person was taking from the jar …

There’s a story about a colleague who used to wrap up and take what he be-lieved to be his well-earned ration of crispbread when he went on holiday. Is this true?

Yes, he took this very seriously. But in fact it was the other way round. He went on holiday for two weeks and when he returned he said he was owed his fort-

31

night’s worth of crispbread. It goes without saying that this was someone with a PhD! But we laughed about it.

Dear Donata, we’ve ended our conversation with this humorous little anec-dote about the “all-too-human” – a quality which is probably the only thing unlikely to ever change. Many thanks for this interesting talk; and we wish you much happiness, good health and all the best for the future.

Interview with Donata Bianco by Corina M. Caminada, secretary at Hiscia Institute

32

We say farewell to: Silke Helwig

Silke Helwig started her work as physician at the Lukas Klinik in 1984, and will retire at the end of 2013. She grew up near Flensburg, Germany’s most

northern city, and after taking her school-leaving exams (‘Abitur’), she first stud-ied chemistry, physics and sport before working voluntarily for a year in a day centre for people with learning difficulties. Subsequently she studied medicine in Kiel, encountering anthroposophic medicine at this time. She did her clini-cal traineeship at the Filderklinik in Stuttgart and at Rissen near Hamburg. In 1983 she first came to the Lukas Klinik on a visiting internship, and later took further training courses in biography work, psycho-oncology, palliative medi-cine and psychosomatic medicine.

Dear Frau Helwig, what drew you so strongly to anthroposophic medicine so early in your career?It was two things: firstly I felt connected with the world of spirit in my child-hood, and was fascinated by questions about the death and prebirth existence of both human beings and animals. I always felt death to be a transition rather than a final end, and my mother supported me lovingly in this view, rather than making it taboo. But only when I encountered anthroposophy did I find outer confirmation of my own perceptions and thoughts about life and death.

The other aspect is the medical one: during a nursing internship in a clinic I was allowed to go on ward rounds with the doctors. There I witnessed very drastic things and realized that under no circumstances did I wish to be in this position myself. On the other hand I had an anthroposophic GP who was an exemplary influence on me. Experiences and meetings of this kind guided me towards anthroposophic medicine early on.

When did you get to know the Lukas Klinik?It was in 1983, when I was a guest physician here for 4 weeks. At the end of my stay, the clinic’s director Frau Dr. Leroi asked me if I could imagine work-ing at the Lukas Klinik. But I had other plans at the time. Then, in the spring of 1984 a letter arrived from the Lukas Klinik saying that one of the doctors was going to retire earlier than expected, and asking me if I would be interested in the post. I was in some upheaval at the time, trying to come to terms with the suicide of a very good female friend of mine, and the cancer of another friend. It was a good moment to embark on something new. But during my induction consultation with Frau Dr. Leroi I was diagnosed with severe hepatitis; and so I was only able to start work in Arlesheim three months later than planned, on 1 November 1984. I began on a one-year contract, without my husband.

“I am ending my outward work at theLukas Klinik, but not my inner connection with it …”

33

You were already married then?Yes, we got married young, but of course he had no residence permit for Swit-zerland, so I decided to come here without him. I quickly realized that the Lukas Klinik was the right place for me, which I am sure had to do with the clinic director Frau Dr. Leroi. As both principal and woman she united these two aspects in an extremely positive way. I very much appreciated her clear, straightforward and structured style, along with her loving, caring nature – her motto was “The patient is king”. She was strict but also tolerant towards things like my wilfulness. In accompanying severely ill patients she improved seem-ingly hopeless circumstances by her great determination and optimism, and I was very drawn to this.

At a very young age I witnessed cancer – but always in a positive way – in my family circle. I am certain this helped me not to feel anxiety in difficult situa-tions. On the contrary, it really motivated me to help. And Frau Leroi’s way of working put me in touch with my ideals again. To this day I have retained a sacred respect for what unfolds between patient and physicians – I mean the destined encounter that anthroposophy speaks of. Steiner refers to this, and to the Christian healing impulse: a space where Christ forces can truly take ef-fect. I have put it very briefly, but there is really a very great “healing quality” to be found in this.

Do you mean that it is not arbitrary which doctor one finds one’s way to as a patient?I do think that. It is always a destined encounter. This has nothing to do with sympathy or antipathy. There is a path of schooling for anthroposophic physi-cians involving what Steiner calls “the courage to heal”, “the will to heal” and “love for the patient” as stances that needs to be developed and are clearly beyond feelings of sympathy and antipathy. Loving interest helps here in over-coming ostensible sympathy or, indeed, antipathy. Of course there can be fric-

34

tions, though these usually resolve by themselves. But as physician I always follow the higher dictates of healing. You see, it is not arbitrary who comes to-wards me and with which questions.

In other words, you journey with each patient, you travel a little way along together?Yes, certainly. I also found it interesting that this form of “relational medicine” has now worked its way into conventional medicine too. While taking a course in psychosomatic medicine I discovered that this very same quality in the doc-tor-patient relationship is regarded as an important factor in recovery.

Does this mean that an aspect of the healing impulses long present in anthro-posophic medicine is now also to be found in academic medical approaches?Yes, but perhaps we should say “found once more”. The terms used are dif-ferent, but there’s scarcely any difference of meaning. This is hugely exciting and promising. At the Lukas Klinik I found a place where I could introduce my own impulses in relation to patient-doctor collaboration. Frau Leroi always supported and encouraged me in this, and allowed the necessary scope for it alongside the strict fulfilment of duties that was also required. And so, a year at the Lukas Klinik has eventually become almost three decades.

Was Frau Leroi still there for a while after you arrived, and did you go on working with her?For four years, yes. And that is when one of the aspects of my work began that became a primary focus of what I did at the Lukas Klinik. In those days we al-ready had biography questionnaires for patients, on which we noted their life experiences, and this fascinated me. I started being more deeply preoccupied with anthroposophic biography work, and thought it would be helpful to use this aid to understanding in a more methodical and structured way.

Can you just briefly explain the nature of anthroposophic biography work?In anthroposophy Steiner describes how life does not unfold at random but ac-cording to certain patterns and laws, in rhythms that apply to all human beings. I like using the image of a house whose construction must obey particular laws but within which the architect has great scope to design and elaborate things as he wishes. Similarly there are certain primary structures, laws, that apply to the life of every human being, but which we each handle individually as “ar-chitect”. This brings the unique aspect of each person to expression. For ex-ample, these common laws are clearly discernible during a child’s first three seven-year periods and imprint themselves into his organic nature. All of us get our first tooth round about the same time; then likewise there’s second den-tition which marks school readiness; and puberty which heralds a first level of – physical – maturity (which Steiner calls ‘earth maturity’). Then comes the

35

end of upward growth which in former times coincided with the “age of major-ity” etc. Subsequently there are further laws but they are no longer so “com-pelling” or “inevitably” realized but fall more within the scope of each indi-vidual’s freedom. The questions that life asks us when we are 21, and the way we engage with them, are quite different from when we are 42.

And anthroposophic medicine takes these rhythms into consideration?It should do. Steiner points out that it is not enough to consider a person before you just at this moment, but that we should try to understand him in terms of his whole life. In the past I took a look at various psychotherapeutic approaches, but I found they lacked a sense of the other’s freedom and the spiritual aspect. It was always important to me to help the other person perceive and acknowledge himself, instead of telling him what is right or wrong, or what he ought to do.

In the spring of 1988 Frau Leroi said that someone would be visiting from Bra-zil. This was Frau Dr. Gudrun Burkhardt whom she had known personally for many years and who had developed a new form of therapy she called “biog-raphy work”. I was able to attend the patient seminar given by Frau Burkhardt, and was hugely inspired by it. In 1989 Frau Burkhardt offered the first course in biography work to doctors in Arlesheim, and over the next five years I took an in-service training course in this work with her. I was able to start using this method immediately with patients.

So you were one of the pioneers in using this form of therapy?Yes. During my training and after the death of Frau Dr. Leroi in September 1988, I was committed to getting biography work properly acknowledged. It was not universally welcomed in the Lukas Klinik. But I worked hard to persuade peo-ple, and above all they saw the positive results of this work in the patients – and so it became accepted as part of the range of therapies.

I imagine that this way of reflecting on your life is in harmony with modern holistic therapies?Yes – patients are more willing to ask questions nowadays, and are definitely looking for something to accompany them in their inner questioning; but not in the sense of “give me some advice” or “let me do it for you”. They really want to find their own path. Women particularly often arrive with such questions, are more open and courageous and wish to explore these issues. But men do so too. It seems to me that cancer encourages such questioning.

Do you find that patients with cancer today view their illness differently from before, and therefore have different questions?That is very clear. If I think back to my medical training, even telling a patient he had cancer was an exception to the rule. The relatives were told, but they

36

were asked not to burden the patient with this knowledge. In those days pa-tients usually had an inkling of it but didn’t wish to know or ask – it was al-most taboo. The grounds for this were to “give the patient some hope”. Later came the approach of suggesting the patient take a trip round the world before it was too late – thus tending to deprive him of hope. Today people subscribe to the ideal of a “shared decision” based on full mutual information: thus not just from the physician, but involving the patient’s views and wishes too.

So this isn’t just true of anthroposophic medicine, but is a question of the prevailing zeitgeist.Precisely. Now patients who come to a consultation will express their own needs or get second opinions. We tend also to speak of “clients” nowadays in-stead of “patients”, though personally I don’t find this so good. But there is a greater trend these days for people to find things out for themselves. I also still have patients I “inherited”, who started mistletoe therapy 50 years ago and are still receiving it. They have their Iscador, are very happy with it, and ask no further questions. But this generation is dying out. And the fact that cancer in-creasingly affects younger people means there is greater self-awareness and that engagement with information media is more self-evident.

Mistletoe therapy is a major part of cancer treatment at the Lukas Klinik. How do you see the role of Iscador in treatment? Did you know anything about it at all when you arrived at the Lukas Klinik?Yes, during my studies, I encountered Iscador during a medical conference in Hamburg where Frau Leroi gave a talk. I learned the ABC of it during my first internship at the Lukas Klinik. And later I became very familiar with it through Frau Leroi and Michael Lorenz. It became the “instrument” whose whole range of possibilities I could “play” on, with trust in its potential.

How did you find working with the most gravely ill patients?I found enormous pleasure in working with these patients in particular. In my view there is scarcely any other field with such rewards for the doctor as this, where one can achieve so much in the broadest sense. I repeatedly heard peo-ple shortly before their death saying that they had never felt so healthy as now. The concepts of “health” and “recovery” acquire a quite different character here. Healing is ultimately something that extends beyond death.

So keeping someone alive is not the primary aim?But yes, it is, always: the primary thing is to sustain and support this pre-sent life, and work to achieve a cure. But there are things that are simply not within our power, questions of destiny. The important thing is that we help maintain life in a way that enables the person concerned to pursue the mean-ing of his developmental path to his very last breath. Our conviction that life

37

continues beyond death plays a very important part in this; and the fact that the smallest step we take in this life has meaning for our further existence. This gives the idea of palliative medicine a quite different significance. It is no longer just a question of departing this life in as comfortable and pain-free way as possible, but rather of how a sick person can pursue his path in life for as long as possible and in the way most fitting for him. And how he can – let me put it like this – approach the threshold of death in a fully con-scious way. Steiner points out that the transition from life into death is the greatest moment of a human life, and that the way we approach this thresh-old has a great influence on all our further existence. This is something that lies very close to my heart.

We spoke before about the courage to heal. I experienced an example of this when a patient was unable to stand any more because her vertebrae had crum-bled away due to tumours. She was a very self-aware woman, the same age as me. I told her that something could be done: I had the will though she herself didn’t to start with. I talked it through with her. She to me: “I’m not sure I still want this. Could you promise me if I do that I can go to Armenia?” This was most unusual. I was concerned with pain relief and to get her up and walking again as soon as possible. And she wanted to go to Armenia, where the infra-structure is poor. As a doctor, this gives you a bit of a fright. How could I prom-ise such a thing? I asked her why she especially wanted to go to Armenia. She replied that she didn’t know why. I said to her: “If it’s in your destiny to go to Armenia, then we’ll manage it.” We did manage it, although it was really an impossible idea. And after being in Armenia, she started a foundation that did a great deal of good. She lived a few more years. But I had to negotiate with her in relation to this step into the unknown. I was unable to promise her any-thing – you feel you’re on thin ice. But I agreed, and the confidence we found helped her to mobilize her strength.

That sounds almost miraculous.Well, what is a miracle? I feel that something miraculous happens when the Christian principle resonates between two people. It is a gift when both peo-ple open to each other so that a power enters from above and helps some-thing to happen. I would personally call that a miracle. But it depends on us offering or creating the space, the vessel for this to enter. This is an in-timate space that can unfold between two people, and when this succeeds as shared endeavour, then we could indeed call it miraculous: cures that are seemingly impossible. Cures also in this life. You can probably see that these things are central to me.

Now the task of the physician in a clinic must surely also include other aspects.Yes, and those are not all things of deep concern, at least not at first glance. I once met a very old anthroposophist who experienced the following during an internship for his eurythmy training in a curative home. As newcomer he

38

was only allowed to empty the chamber pots and clean shoes. This greatly wounded his vanity. But then he decided to make the best of this and see what he could learn from it. He started studying the residents’ shoes, seeing

how the soles were worn, then be-gan to think about how each person walks and what each might look like. I was very struck by this. That is why I try to see what I can learn especially in difficult situations. And so in the Lukas Klinik I have taken on many tasks such as student projects, quality management, tariff supervision and a great deal more. And I have learned a great deal from these supposedly “lifeless” things about organization, structures and so on, which has made a positive impact even on my work with patients.

The annual report – which we edit together – is also part of these tasks that you have taken on. It must have been ten years now.There it’s a matter of working with

words and text, something I have always enjoyed. When I agreed to take on the annual report initially, it was just as continuation of a supervising role. But I have always felt the impulse to develop and change things, or improve them. I found an excellent partner in you and together we have been able to introduce some new impulses. The work, which was just a duty to begin with, became a pleasure. I hope that you will carry on this work in the same way.

Do you have firm plans for any projects when you stop work at the Lukas Klinik? It will be a new phase in your life …Yes, but I can see that the transition will require some effort, and that detach-ing myself will need to be done carefully, step by step. The Lukas Klinik was the centre of my life for all these years, and has determined everything else. I just mean by this that I have been involved all round as a physician.

But then surely it will be hard for you to leave?Very much so. But I must also live, which is something I think is right for my patients. It is time to go now, and so I’m going. And that’s good. I can take time to make my departure, and go calmly, though this doesn’t mean I won’t feel the pain of leaving. I am ending my outer work at the Lukas Klinik, but not my inner connection with it.

39

And what will you do next?One thing I’d like to do is run a small practice for patients who want to come, but really only a small one so as to have time for other things.

Such as?I’d like to realize my KULULEKA pro-ject.

KULULEKA?Yes, the word means roughly “free yourself” and comes from the Afri-can language of Xhosa, Nelson Man-dela’s language. The impulse arose many years ago in connection with combating cancer through biogra-phy work and artistic therapies. It was really always a matter of “be-coming free” at all levels; and in ad-dition, many patients were unable to pay for the therapies they needed be-cause the health insurers did not fund them. I felt there was a great need here. To enable people to get the care they needed, I started collecting funds. The project had to have a name and I came upon the term “Kululeka” as if by chance – a word whose meaning also contained a great love for southern Africa …

… which is a theme we ought to touch on …… yes; and after various reflections this became an association. Its aim is to make it possible for people seeking these therapies to receive them, for as long as, and in whatever way, they need them. The idea originally came about in re-lation to the Lukas Klinik since these outpatient therapies, specifically, are of-ten not funded. And now it is to become an independent project, though pa-tients from the Lukas Klinik can certainly participate (see below for more in-formation).

And I also want to write. I’ve probably got boxes full of material that needs working on – all stories about people. And then I’ll just see where this leads me.

No doubt back to Africa again? Would you like to tell us briefly how you fell in love with it?When my husband was young he lived in southern Africa. We first went there together in 1996. I still remember very clearly my sense of profound inner

40

shock – a feeling of connection with this land – when I first set foot upon its soil. Its landscape, the desert with its plants, animals and people! For people who come from our culture it can have a healing quality. For me, there is noth-ing more helpful, if one is anxious or does not know how do carry on, than to go out into a landscape like this. But it is also challenging.

But let’s come back from Namibia to the Lukas Klinik for a moment. Is there anything else in your life as a physician at the Lukas Klinik which has particu-larly moved you in retrospect?Oh, a great deal. I know so many stories that have moved me. Every patient and his story is a book that I can open and plunge into.

But the following is something I’d like to relate – that is personally important to me in relation to anthroposophy:

When taking part in further training courses outside of anthroposophic medicine, I have repeatedly encoun-tered very important new approaches, and realized how vital it is to build bridges and seek dialogue. Each indi-vidual has to ask himself how he can make his particular contribution to this, how he can step outside of his usual circle. How do I engage with the other in a real conversation? Today we need communities where each indi-vidual can make his contribution, and not just one individual. This places the focus on the whole. Even the run-ning and management of a clinic to-day ought to be a community concern.

Do you think this would be a good idea for the Lukas Klinik?What I wish for the Lukas Klinik is

that it rises like a phoenix from the ashes again, wholly renewed.

In biography work, there is a law in which, at around 49 or 50, one’s tasks, bonds and obligations from the past come to an end. I experience this to be so now at the Lukas Klinik, which will celebrate its 50th birthday in 2013. En-tirely new, future-oriented powers need to arise, be resurrected. And this re-quires people to enthusiastically grasp the new, and to do so in community. The Lukas Klinik is a good place of peace and healing. With patients I have often seen how things deteriorate, that their life seems to be over – and yet

41

something quite new arises instead. This is how I see things now for the Lukas Klinik.

Hilde Domin writes: “I placed my foot on the air – and behold, it car-ried me.” What’s needed is courage, taking steps with enthusiasm, without prior certainty. That’s what I wish for the Lukas Klinik. And I say this with great gratitude for all the valuable ex-periences and learning opportunities I have had here, above all in encoun-ters with my patients.

Let us trust this will happen, and let us send the Lukas Klinik our best thoughts and wishes; and to you too of course, dear Frau Helwig, for your new phase of life after almost 30 years as a physician at the Lukas Klinik, we wish the same courage and strength you have already shown in the past. Warmest thanks for this interesting conversation.

Interview with Frau Helwig by Corina M. Caminada, secretary at Hiscia Institute

Information about Kululeka: www.kululeka.ch (starting September 2013)

42

43

The Lukas Klinik – from the early days …

44

… to now

45

46

The Institute for Clinical Research ICR / Institut für Klinische Forschung, IKF Berlin

In the mid-80s, anthroposophic physicians began to use the immune-mod-ulating, therapeutic actions of Iscador® and other mistletoe preparations

to treat AIDS patients too. At this period, medical research into an effective AIDS treatment was still in its infancy. The earliest case studies of previously healthy young men with opportunistic diseases such as pneumonia or Kapo-si’s sarcoma were not published until 1981, and in 1982 the HIV virus was first recognized as the trigger of what came to be called “Acquired Immune Deficiency Syndrome”.

The beginnings

In contrast to the use of mistletoe therapy in oncology, which could rely on decades of experience relating to host tree and dosage, therapeutic proce-dures were still entirely new in this field. It quickly became apparent that no adequate knowledge would be gained without relevant systematic research. Yet mistletoe therapy in oncology faced similar problems. Revision of medi-cines law in 1976 meant that all mistletoe preparations in Germany now fell under the legal stipulations of “notional registration” – meaning that, within

A bridge towards general recognition of complementary medicine

47

12 years, manufacturers were required to gather data demonstrating the med-icines’ safety and efficacy, in line with current scientific and technological knowledge. The “current state of knowledge” also already involved key ele-ments of “Good Clinical Practice” guidelines, that is, controlled, prospective studies in line with predetermined study protocols, with transparently doc-umented data recording and evaluation. Although Iscador® had been intro-duced into medicine as early as 1920, and for decades had been further de-veloped, optimized and successfully used in treatment, very few study results existed that met these quality criteria.

On 10 May 1994, therefore, members of the Society for Cancer Research (Ver-ein für Krebsforschung) in Arlesheim, Switzerland – including Dr. Johannes Hoffmann, Dr. Juergen-Johannes Kuehn, Erhard Strom, Dr. Michael Werner and Dr. Gerhard Schaller – founded the Society for Oncological and Immu-nological Research. This changed its name to the “Society for Clinical Re-search” (Gesellschaft für Klinische Forschung, GKF e.V., Berlin) on 26 May 2003. To realize the aims of this charitable association, as enshrined in its statutes, the Institute for Clinical Research (Institut für Klinische Forschung, IKF Berlin) was established at the same time, and known originally as the “In-stitute for Oncological and Immunological Research”. In July 1994, the insti-tute started work with four staff, initially, in premises at Moabit Hospital in Berlin, under the direction of the Dutch physician and cofounder of the as-sociation, Dr. Robert Gorter.

Research to secure recognition for mistletoe therapy

The founders of the sponsor association and the institute were of course pri-marily concerned to gather good quality study data for Iscador®. But at the same time they also wished to build a bridge between complementary and classical scientific medicine by designing rigorously controlled and interna-tionally accepted clinical studies, thus seeking to improve acceptance of this medicine by mainstream physicians in academic medicine, and by local au-thorities and health insurers. A further formulated aim was to draw on inno-vative study designs in the clinical research repertoire that would do justice to complementary medical approaches.

These additional goals also dictated the decision to choose Berlin. At the time, this location was a long way from the ‘strongholds’ of mistletoe re-search between Dornach, Switzerland and Witten/Herdecke in western Ger-many. But following the German parliament’s decision of 20 June 1991 to move the parliament to Berlin, this location was close to the centres of power and decision-making. In September 1997 the institute moved its headquar-ters to the Charlottenburg district of Berlin – 19 Hardenbergstrasse – in the immediate vicinity of the Zoological Gardens railway station. In 2012, hav-ing outgrown this office, it moved again to neighbouring modern premises at no. 20.

48

Hemp kindles scientific interest

Soon after the institute had taken up its work, a second research emphasis developed under staff member and subsequent institute director Dr. Martin Schnelle. This focused on Cannabis sativa, the traditional medicinal plant hemp. During his previous work at the University of California in San Fran-cisco, Dr. Gorter had become aware of its therapeutic potential for treating loss of appetite and emaciation, symptoms apparent at the time in AIDS pa-tients, and today still in many patients at an advanced stage of cancer. Al-though the chief active therapeutic constituent of Cannabis sativa – Tetrahy-drocannabinol (THC) – was already registered as an isolated, synthesized preparation for treating AIDS, and in chemotherapy, Hiscia research institute assumed responsibility for pharmaceutical development of a standardized whole-plant extract, later registered under the name of “Cannador”. After in-itial studies on tumour patients, in 1999, this medicine’s further development took on a dynamic of its own, and a new direction, after a request from the Royal Pharmaceutical Society in Britain to use Cannador® in a large-scale pla-cebo-controlled study on spasm and pain reduction in multiple sclerosis (MS). The encouraging but not formally sufficient findings of this comprehensive study convinced the company Weleda to undertake an equivalent confirma-tion study in 2005, as cosponsor alongside the Society for Clinical Research. The results were sufficiently positive to conclude the study early, in 2009. But subsequent efforts to secure a market permit for Cannador® for MS treatment, turned out to be more laborious and expensive than anyone had expected. Since medicines registration authorities did not, largely, class the scientific literature on tolerance and safety of Cannabis sativa as commensurate with current findings in science and technology, long, costly research on animals will be required, which cannot at present be undertaken. Unfortunately this also affects further potential indications for Cannador®, such as tumour-re-lated pain, anorexia and cachexia, as well as the symptoms of herpes zoster or Crohn’s disease, for which studies were already underway or in planning.

The ups and downs of clinical research

Parallel with the studies on cannabis, the Institute for Clinical Research con-tinued clinical research on Iscador®. However, the AIDS indication in this field had to be relinquished since development of HAART therapy (highly ac-tive antiretroviral therapy) enabled development of AIDS symptoms to be sup-pressed indefinitely, albeit without entirely curing the HIV infection. Since it would be unethical to withhold HAART therapy from AIDS patients with de-veloped clinical symptoms, the necessary goal parameters were lacking for providing objective proof of mistletoe therapy’s efficacy.

The studies on subcutaneous mistletoe therapy, for their part, encountered the great obstacle that in Germany up to 80 percent of cancer patients use Isca-dor® or another mistletoe extract at least once during the course of their ill-

49

ness. The wide availability and high degree of recognition of mistletoe ther-apy, however, frequently mean that patients are unwilling to participate in a randomized controlled study. Physicians too, primarily those who have much experience of mistletoe therapy, often refuse to withhold from their patients a form of treatment they believe to have proven efficacy. Over the years, due to lack of patient recruitment, studies on subcutaneous mistletoe therapy for cervical dysplasia, and lung and breast carcinoma, have had to conclude be-fore reaching the planned number of cases, end prematurely, or be halted be-fore the start of recruitment.

Consequently, the Institute for Clinical Research carries out such studies in countries where Iscador® is less well known, not registered or not even avail-able. Here the preference of patients for mistletoe therapy is less overt, and so they are willing to participate in a control group without mistletoe ther-apy over the long term. In a study on patients in Bologna/Italy receiving Is-cador P® following complete surgical removal of recurring osteosarcoma, a significantly reduced relapse rate was observed after one year. In Serbia, a country with no access to mistletoe therapy, a study was successfully car-ried out over recent years on use of Iscador Qu® to treat patients with ad-vanced pancreatic sarcoma. An interim evaluation of 220 patients not only showed a marked increase in survival time, but also substantially fewer and weaker tumour-related symptoms, and a higher quality of life. The last of the 376 study patients is expected to conclude his participation in May of this year. These positive findings mean that further randomized studies are now being prepared in both Italy and Serbia in relation to a range of can-cer indications.

Research broadens its vistas

Clinical research on mistletoe at the Institute for Clinical Research is not lim-ited to its registered subcutaneous application for oncological indications. Other indications such as HPV and HCV infection, chronic fatigue syndrome or paraplegia-associated infections have been or continue to be the subject of clinical Iscador® research projects. Other forms of application such as in-travenous, intrapleural or intravesical use have also been studied in the con-text of smaller-scale pilot studies. These forms of application are generally undertaken by physicians in hospital conditions, and do not elicit such di-rect or immediately observable reactions at the site of application. The main obstacle to use of a placebo preparation is therefore removed by this means, enabling a return to the gold standard of conventional clinical research – the prospective, randomized, placebo-controlled study. Placebo administra-tion likewise largely prevents patients in a control group prematurely break-ing off their participation in a study through disappointment at not receiving the treatment they expected. Unlike “normal” Iscador® therapy, non-subcu-taneous mistletoe therapy cannot, either, so easily be carried out by patients themselves outside the parameters of a clinical study.

50

Yet clinical mistletoe research has a still wider compass. Some other prepara-tion forms of the Iscador® drug substance – e.g. in highly concentrated form, as ointment, gel, suppository or ovule – are the subject of initial or planned clinical studies. Other pharmaceutical developments, such as triterpene prep-arations, are foreseeable candidates for further research. Here, given the lim-its on financial resources, it is a matter of finding a middle way between li-cense-securing studies in the field of subcutaneous mistletoe therapy on the one hand, and potential permit-enlarging studies for new indications, appli-cations or galenics on the other. At the Institute for Clinical Research, the goal of these experimental studies – to build bridges between complementary and conventional medicine – does not stop with mistletoe and cannabis prepara-tions. Other collaborative projects with anthroposophic medicines producers involve evaluation of clinical tumour registries and databases, plus clinical studies and application observations with homoeopathic or phytopharmaceu-tical preparations. Over the years, also, emphasis has been placed on devel-oping clinical studies on non-medicinal therapies and personality assessment methodologies within anthroposophic medicine. At Havelhoehe district hos-pital in Berlin and Charité hospital, current collaborative projects are ongo-ing on eurythmy therapy and rhythmic massage, as well as multimodal ther-apy approaches including aerobic training, sleep therapy, psycho-oncologi-cal counselling and painting therapy.

Clinical research needs partners

The Institute for Clinical Research in Berlin currently employs nine perma-nent staff and a varying number of student auxiliaries. Besides the institute manager, it has the following departments: medicine (1 staff member), biom-etry / IT (2 staff), medical documentation (3 staff) and administration (2 staff). With its decades of expertise, the institute is able to support its clinical col-laborative partners in study planning and preparation, approval applications, study realization, data documentation, processing and analysis, and in au-thoring study reports and other publications. It supervises trainees, graduates and PhD students, mainly in the fields of medical documentation and human medicine research. In the course of various collaborative projects it has ac-quired a reputation as constructive, reliable partner in the field of integrative medicine, and regularly receives external requests to advise its collaborative partners and their colleagues on questions of methodology. The current direc-tor of the Institute for Clinical Research, Dr. Marcus Reif, has been appointed as expert for biometry and clinical study methodology to the International Re-search Council of the Medical Section at the Goetheanum – for instance in relation to development of the Masterplan II application to Software Stiftung.

The Society for Clinical Research is now approaching its 20th year. Through-out this period it was in the best possible hands of its founding director Dr. Michael Werner, for many years supported equally reliably by deputy director Rainier Dierdorf. This quality of reliability is also reflected in the remarkable

51

continuity of the institute’s staff structure. The Society for Cancer Research has had a long, professional association with the Institute for Clinical Research, extending beyond medical research and the European domain. This associ-ation will be further strengthened in future projects. This proven partnership is the basis for sound confidence that the Institute for Clinical Research and its staff are well placed to successfully advance clinical research and thus make an important contribution to improving cancer and immune therapies.

Dr. rer. nat. Marcus Reif Director of the Institut für Klinische Forschung, IKF Berlin

52

APMA – the French patient association for anthroposophic medicine in Paris

In recent years we have published in our patient association’s bulletin some very telling accounts by patients who describe the beneficial effects of their

stay at the Lukas Klinik. This year, the Lukas Klinik and Hiscia Institute have given us the opportunity to offer the readers of their annual report some in-sight into our French patient association and its work. We thank them for this. Here we look back firstly at the origins and development of our organ-ization.

Founding motives

Since the eighties, the difficulties involved in securing health insurance fund-ing for anthroposophic medicines have multiplied. The need therefore arose for users of these medicines to form an association to defend their interests.

The patient organization APMA (Association de Patients de la Médecine An-throposophique) was founded in 1982. When the statutes were revised in 2010, its aims were formulated as follows: “The association’s aim is to give patients access to a form of medicine encompassing the human being’s body, soul and spirit, as envisaged by anthroposophic medicine in all its applica-tions.”

The activities of APMA are founded on a range of civil values:

• The right to self-determination as enshrined in the European Union’s Char-ter of Fundamental Rights

• Self-responsibility and commitment to preventive healthcare• The right to choose therapies in the context of medical pluralism: responsi-

bility can only be exercised in freedom.

The APMA currently numbers nearly 2000 members and runs an office that answered over 4000 enquiries in 2012 (phone calls, e-mails, letters, brochure orders).

Publicizing the benefits of anthroposophic medicine

In medical circles in our country, anthroposophic medicine is almost entirely ignored, as is the distinctive nature of its medicines. These are regarded as merely homoeopathic remedies. Patients who use anthroposophic medicine of-ten complain that they meet with disdain, ironic dismissal and incredulity not

Anthroposophic medicine in France: a stony path

53

only from those around them but also from the medical fraternity and health insurers. Patients find it hard to locate physicians with an anthroposophic ori-entation. One of APMA’s first tasks involves making this information availa-ble. At the same time it provides information about current rules for the fund-ing of medicines.

APMA organizes talks and presentations for patients who wish to learn more about our approach to medicine, and publishes research in its twice-yearly bulletin. Brochures in the series “Conscience et Santé” deal with many diverse themes relating to illness, therapies and social developments. Based on a spir-itual view of the human being, reflections, first-hand reports and specialist ar-ticles highlight new perspectives that can enrich both individual and commu-nity life. Health, after all, is founded on a capacity to develop our own distinct outlook, questions, decisions and ways of living.

This series of publications also includes some French titles issued by an-throsana, our sister organization in Switzerland. anthrosana reciprocates by distributing APMA titles in French-speaking Switzerland. One of our prime con-cerns has always been to give patients fully comprehensible information about all therapeutic options within anthroposophic medicine.

The APMA also seeks to nurture solidarity and a sense of responsibility amongst users of anthroposophic medicines in freely choosing their preferred form of treatment, and supporting the association’s aims. Access to information is an important part of freedom of choice. It is for this reason that our bulletin re-ports on initiatives, advances and campaigns necessary for publicizing this form of medicine and its therapeutic potential, and enabling it to find a foot-hold within contemporary medicine.

Recognition of anthroposophic medicine in France

Representatives of APMA have repeatedly made overtures to the health minis-try and the national body of health insurers to publicize anthroposophic med-icine, show it in a credible light, seek its recognition and promote patients’ ex-pectations of freedom of choice. In the course of efforts to secure permits and reimbursement for medicines, it has become apparent that the prime empha-sis must be on the recognition of anthroposophic medicine itself.

The APMA has undertaken several actions:

• to achieve costs reimbursement based on equal treatment for people in re-ceipt of benefits, irrespective of the medicine they choose.

• to organize protest petitions (against refusal of funding and cancelling of medicine permits following the mad cow disease scandal).

• to obtain official rulings on medicines used in anthroposophic homoeopa-thy (adjustment of regulations under national law, permit procedures, etc.).

54

These actions and interventions have often been supported by patient cam-paigns: letters to members of Parliament, political pressure groups, signing of petitions etc. At every election for national or European MPs we have ques-tioned candidates and urged our members to do the same. It is important to show decision-making bodies how seriously citizens regard the issue of choos-ing their own medicines.

One example: In April 2011, in the midst of the scandal surrounding the weight-loss drug “Mediator”, which led to the deaths of between 500 and 2000 peo-ple, APMA addressed a letter to the President of the Republic and the health department. Following this, we were invited to put our case at the department of health in relation to “a patient campaign on behalf of complementary med-icine, arising from loss of trust in allopathic medication (disclosure of the side effects of Mediator, required monitoring of numerous medicines, disclosure of conflicts of interest …)”. On this occasion we submitted important scientific documentation of studies showing the benefits of anthroposophic medicine, and summaries of official presentations on anthroposophic medicine to French and European medicines agencies.

Helping to shape European health policy

The development of the EU and elaboration of permit conditions for medicines has opened up an important new field of action for patient organizations and their partners (physicians and medicines producers). One event in 1992 is char-acteristic of these developments: a reference to anthroposophic medicaments in the preamble to the guidelines on homoeopathy. This was the first time that these medicines had been mentioned in a European legal document – a fact that proved very helpful in France in efforts to publicize anthroposophic medicine.

A further step was the formation in 2000 of a federation to protect the interests of anthroposophic medicine. EPFAM (European Federation of Patients’ Asso-ciation for Anthroposophic Medicine) is an umbrella organization connecting several national patient organizations in Germany, Holland, Switzerland (an-throsana), England, Sweden, Belgium and other countries. APMA is a founding member of EPFAM and since its inception has acted as this federation’s secre-tariat in European campaigns.

EPFAM seeks to promote its patients’ interests in the formulation of European health policy, and to present the benefits of our approach to medicine to Euro-pean authorities, so as to achieve appropriate legislative safeguards for medic-aments that as yet have no protection. As a member of the health policy NGO EPHA (European Public Health Alliance), a partner of the EU Commission, EP-FAM makes a contribution to shaping European health policies.

All these activities are continuing and becoming broader and more differenti-ated in scope. But the most important thing has still not been achieved. Cur-

55

rently we regret that legislation is not yet in place to safeguard anything like the whole range of anthroposophic medicines. These loopholes pose the risk that an important number of specific medicaments in this medical approach may disappear altogether.

The demand for freedom of choice in treatment

Medical freedom of choice should not be limited in any way. It is the duty of European institutions and individual countries to protect freedom of choice and provide patients with the necessary guarantees for the safety, efficacy and com-mercial viability of the medical approaches they choose. In fact, too little ac-count is taken of complementary medical approaches under professional prac-tice and medicine permit regulations. Our patients find that their free choice of therapies remains at risk.

Legal regulations geared to a majority view are unfortunately poorly suited to the welfare of minorities. Social vigilance is therefore required – as practised in the ELIANT Alliance launched by Dr. Michaela Gloeckler to represent the fields of agriculture, education and medicine. All these suffer from inadequate and often obstructive legislation. The ELIANT organization, with which Euro-pean EFPAM and the French APMA are affiliated, collected a million signatures that were submitted to the EU Commission on 13 May 2011.

People who choose anthroposophic medicine are seeking a new health par-adigm. Back in 2004, in response to a EU Commission survey, we outlined – under the title ‘Health for All’ – the need for a new paradigm that would again accord a fitting place to a culture that promotes health. Below are a few sen-tences from our submission, which was posted on the Commission’s website for a while: “We think that the delay in acknowledging non-conventional med-ical approaches amongst member states can partly be explained by a mentality that primarily regards health as the combating of illness (pathogenesis) and is too little aware of prevention (salutogenesis) … Health policy, commonly ori-ented to the harm caused by tobacco, alcohol and drug addiction, to severe pathologies and new diseases, takes far too little account of the health poten-tial arising from the responsible conduct of citizens who choose nonconven-tional medical approaches in Europe.”

In this regard we welcome initiatives in Switzerland, where calls for com-plementary and alternative medicine are being promoted by democratic means.

New networks and partnerships

In our battle for free choice of therapy, we have encountered other, related movements such as homoeopathy, phytotherapy, acupuncture, Chinese medi-

56

cine and other traditional schools of medicine. Thus we have found new part-ners and begun to make join public representations on behalf of comple-mentary and alternative medicine (CAM is the abbreviation used in French and English as an umbrella term encompassing such methods). Inclusion of CAM in the European research programme represents a culmination of these positive developments, which are giving rise to new organizations that seek to gain acceptance for CAM, and are active in the research field. They include the anthroposophically oriented ESCAMP (European Scientific Co-operative on Anthroposophic Medicinal Products) for anthroposophic me-dicaments (www.escamp.org) and CAMbrella, a network for complemen-tary and alternative medicine (www.cambrella.eu). On 29 November 2012, this organization presented its work and future aims to the European parlia-ment.

What does the future hold?

Although a growing num-ber of patients experience the benefits of CAM at first hand, information about the availability of these medical approaches in Eu-rope remains poor. CAM-brella highlighted this fact in a recent press release.

In Europe in general, de-spite everything, progress is apparent in this process of growing awareness. In France, by contrast, we have noted an increasing

mistrust amongst the French authorities and a hardening of views. CAM ap-proaches are also succumbing to the perfidious influence of the big pharma-ceutical corporations, which produce chemical drugs and fear competition from natural medicine.

Since anthroposophic medicine is currently struggling in an increasingly diffi-cult environment, we need campaigns to

• enact legislation guaranteeing the right of physicians, nurses and art thera-pists to practice their medical profession,

• safeguard the manufacture, distribution and health insurance funding of medicines,

• inform patients who may have been misled by too little or false informa-tion.

57

Summary: action is more necessary than ever!

We would like to draw the attention of our European friends to the cultural mi-lieu in France in which any medical approach is rejected if not founded exclu-sively on the molecular model that reduces the human being to his physical and chemical dimension. This dismissal is directed in particular at anthropo-sophic medicine, which in April 2011 was placed on a list of dubious medical approaches under the pretext that it posed the risk of being used to promote a sect – an accusation issued by the governmental ‘sect-watch’ body Miviludes (Mission interministérielle de vigilance et de lutte contre les dérives sectaires).

This suspicious-sounding categorization is one that burdens the whole anthro-posophic medical movement in France. Some physicians have been summoned by their medical association or health insurance bodies to give an account of themselves. The situation is compounded by the fact that medicines are con-tinually succumbing to tougher laws so that a significant number are no longer available – especially in ampoule form.

The APMA pursued these issues and turned to the president of Miviludes, Serge Blisco. Appended to our letter to him was a three-page submission demonstrat-ing the widespread international demand for anthroposophic medicine in or-der to underline the importance of our movement. Blisco replied that in France there was no accepted evaluation of anthroposophic medicine and that it was the duty of his department to protect patients against practitioners who were either insufficiently trained or suspect. It is noteworthy that anthroposophic medicine was included on the blacklist without any discussion with the pro-fessionals affected. Since this reply did not satisfy us, we turned once more to the health minister. Below, as information, a few extracts from our letter to him:

“We are astonished that it is possible in a country that adheres to the rule of law that anthroposophic medicine can be included on a list of ‘health and sectarian dangers’ (‘Santé et dérives sectaires’) without any prior evaluation or official hearing of those affected, and ask that you use all available means to

• remove anthroposophic medicine from this list,• put legal safeguards in place to ensure that the professional associations and

physicians practising anthroposophic medicine can continue to use, teach and train in this approach,

• ensure that unprofessional conduct is not wrongly ascribed to anthropo-sophic medicine such that its reputation is harmed, as happened to the den-tist referred to by Mr. Blisco.

To reconcile patients with the field of medicine, we urge the authorities to open up the health system to complementary medical approaches, and in this way re-spect patients’ free choice of treatment. Anthroposophic medicine is very well placed to make a contribution to the development of citizens’ health, both as regards therapy and economic viability.

58

Let us remember that the Council of Europe urged in its resolution of 4.11.99 – which, though not legally binding nevertheless outlined the ethical way for-ward – that nonconventional medical approaches, including anthroposophic medicine as a named medical approach, be included in its health system.”

The set of arguments supporting anthroposophic medicine was again appended to this letter. After four months, we received a reply which referred us back to the “sect monitoring” department Miviludes. Thus, in the “land of human rights”, we see how “democracy” goes round in circles!

APMA would be glad to provide readers of this annual report with the full cor-respondence between ourselves and the French authorities.

Colette Pradelle, President of the APMA

APMA13 rue GassendiF-75014 ParisTel. / Fax: +331 40 47 03 53 contact@apma.frwww.apma.fr

59

Introducing the cancer care foundation in Lahore, Pakistan

When a lab report comes back with tests showing positive for

cancer, a patient can feel this to be a death warrant. Patients often feel dev-astated, experiencing the cancer diag-nosis as depriving them, in an instant, of their hopes in life.

The clinic and research centre at Arlesheim helps cancer patients find con-fidence to fight the disease. The Lukas Klinik’s multidisciplinary programme has been innovative, and until quite recently there was nothing compara-ble to it.

In Pakistan, our clinic was a forerunner in working with this concept, though back in the 70s, my father, the late Dr. Akhter Husain, had already initiated treatment for cancer, alongside all other diseases. Back in 1939, it was run as a homoeopathic clinic, but after the emergence of Pakistan it grew greatly in size and earned a reputation and much goodwill for admitting cases that seemed desperate or hopeless. Later Dr. Akhter Husain extended the pro-vision to include cancer cases, which also proved rewarding. He was keen to see me follow in his footsteps so that I too might benefit from the expe-rience and insights of world-class scientist Dr. Rita Leroi.

As early as 1977, The Verein für Krebsforschung in Arlesheim proved to be a blessing for us in guiding our approach to the supportive treatment of cancer. The late Dr. Rita Leroi von May was a heavenly personality who advised on medicines and shared her experience and expertise. This col-laboration grew stronger still after the death of the devoted physician, Dr Akhter Husain.

Most of the patients in our clinic arrive with acute problems, and a num-ber of cases are also admitted with overdoses or harmful self-medication – with damaged liver or kidneys or both. Cancer cases are given special care, with extra in-patient counselling and advice for managing the disease at home.

From Hippocrates to Rudolf Steiner, approaches to curing disease and en-hancing wellbeing have had a rational basis. Approaches to patient treat-ment should be gentle, enduring and body-friendly. This becomes still more vital in the modern age with the growing number of diseases. Modern med-

Total wellbeing again

60

icine has demonstrated its competence, though this tends to be in one-sided ways.

The conventional approach to cancer treatment has proved to be pallia-tive or superficial. In fact its understanding of the problem is irrational and unrealistic. The human being is not a mechanical structure, but instead a complex organism whose composition of mind, body and spirit need to re-main in harmony. Equilibrium between the nervous system, endocrine sys-tem and immune system is indispensible. To achieve this in the process of curing a disease, various aspects need to be considered.

Primary attention must be given to the diet plan with a diversified menu that takes account of each individual’s temperament and tolerance. Diet should be simple, nutritional and easily digestible. Foods containing re-fined flour and sugar are excluded due to questionable manufacturing pro-cesses; and likewise poultry. A balanced diet comprising proteins, starch, dairy products and nominal fats is advisable. Certain detoxifying foods can also be included.

The most vital part of the holistic concept is caring for the mind-body cor-relation. Several such approaches are practised at our clinic, ranging from yoga, biofeedback, meditation, Zen training and alpha-wave therapy to Reiki. In Arlesheim’s Lukas Klinik, following the anthroposophic approach, the form of therapeutic movement known as eurythmy is also practised.

In our clinic, patients are taught the above-mentioned relaxation thera-pies, many additional forms of which – such as deep breathing exercise in corpse pose, alternate nostril breathing, aerobic exercises, meditation, vis-ualization – are now also practised at other centres. It is a question of find-ing what best suits each individual patient.

‘Autogenic therapy’ is a quick and easy form of relaxation that verges on meditation, and can be used as a long-term therapy and as a quick diffuser of stressful situations.

One of the oldest natural therapies is hydrotherapy utilizing hot tubs, steam baths, and Epsom baths etc., of which the Sitz Bath is most common and practical. Sometimes mud baths are also recommended, and well suited in detox programmes.

The efficacy of massage is undeniable, with its varied and skilful techniques. The oils used have medicinal effects, e.g. sesame oil is warming and inhibits polyuria. Poppy-seed oil has sedative and analgesic effects. Likewise laven-der oil and sandalwood oils are soothing and tranquilizing. It is noteworthy that soft massage movement create soothing effects while brisk movements promote stimulation. The direction of movements is towards the heart so as to promote venous blood circulation.

61

Aromatherapy also has long historical antecedents, dating back to 7000 BC. Using various parts of a range of plants, it helps enhance wellbeing and har-monize mood. Lavender helps good sleep while sandalwood is an antide-pressant. Cold and flu symptoms can be relieved by steam inhalation with eucalyptus or tea-tree oil. Similarly, ginger steam is useful for warming the organism in miserable weather.

Reflexology and acupuncture may help a patient in complaints such as nau-sea, vomiting, insomnia, indigestion and headache associated with conven-tional cancer treatment. Bach flower remedies are a recent addition to the range of plant remedies. These are best suited for individually addressing particular moods and nuances of soul, such as honeysuckle for homesick-ness and nostalgia, gentian for pessimism and despondency, olive for com-plete exhaustion and rock rose for conditions of extreme terror and panic.

Finally, herbal teas are also valuable as natural herbal remedies. Ginger tea is good for morning and travel sickness, peppermint tea for indigestion, flat-ulence or colds. Similar benefits can be achieved with a compress or poul-tice – the first being a cloth soaked in herbal extract and the second an herb paste, both applied to the skin.

Besides such remedies, creative activities are vital for enhancing a patient’s wellbeing. These can include: model making, painting, playing music or even autobiographical writing. Such activities, again individually match-ing each patient’s needs, help address inner problems and obstacles and so smooth out the ‘wrinkles’ in the mind.

The latest addition to our range of diagnostic tools is the Royodoraku sys-tem, based on scanning the balance of vital forces in acupuncture merid-ians; this is also known as electro-meridian imaging. It produces health graphs of all body functions.

For a lasting cure, anthroposophic medicine is currently in great demand, and is best complemented by expertly prescribed homoeopathic remedies. Tumour regression is often achieved by these means and survival time may span 5–10 years, even in the elderly. The USA’s National Cancer Institute is now sponsoring research into such work throughout the world; but Dr. Rita Leroi was a high-calibre person who inspired our research in the early 80s, and helped us achieve remarkable successes.

At our clinics we aim to serve patients by unparalleled efforts, leaving no stone unturned in providing the best cancer care in South-East Asia. Re-cently we relocated our larger clinic to increase the scope of our work in proximity to a world-class cancer centre, SHOKAT KHANUM CANCER HOSPITAL AND RESEARCH CENTRE, founded by international cricketer Imran Khan. This centre includes our concept and research in its confer-ences.

62

At the last MECC conference in Cyprus in 2010 our work was much applauded. It is the only centre in this region that collabo-rates with the Verein für Krebsforschung in Arlesheim. The INCTR conference in 2009 at Antalya, Turkey, was also encouraging: participants there were impressed by our holistic approach to cancer care. Such an approach, strangely, seems scarcely to fig-ure anywhere in neighbouring countries such as India, Iran and the Middle-East re-gion.

We strongly hope that our untiring efforts to inspire researchers in Asian and other de-

veloping countries will lead them to reconsider their conventional approach to supportive cancer therapies.

Dr. Afsar Imam SayyedDirector of the Cancer Institute of Pakistan

63

Dr. Jürgen-J. Kuehn worked at the Verein für Krebs-forschung from 1.12.1984 until 28.3.2013, focus-

ing on research and the direct application of research findings to patients.

Dr. Kuehn could be found working at the Lukas Klinik day and night, often even when he was supposed to be on holiday. He undertook weekend and night-time du-ties right up to the end of his years of service.

Anthroposophic medicine was invariably at the fore-front of his work; but he also followed scientific ad-vances in medicine with equal interest, and could therefore always offer useful advice in this field.

His chosen field of research was immunology, specif-ically the aspect of ‘fever’. Anthroposophic medicine has gained greatly from his work, as testified by count-less publications. Dr. Kuehn was always there for his pa-tients, concerning himself tirelessly with their welfare. As a physician he was dedicated to life, and thus a ve-hement opponent to the active euthanasia movement.

We take our farewell from a very highly esteemed colleague as he enters on retirement, and we wish him much pleasure and good health in his new phase of life.

Our best thanks go with him for his important achievements at the Verein für Krebsforschung.

The college of physicians at the Lukas Klinik

Farewell to: Dr. Jürgen-Johannes Kuehn

64

Dr. Ulrich Reichert worked at the Verein für Krebs-forschung from 9.4.1985 to 30.6.2012.

During these 22 years, he accompanied many pa-tients in their journey through cancer. In the context of KIKOM (complementary medicine collegiate), he also represented anthroposophic medicine and the Lukas Klinik at Bern Hospital.

Dr. Reichert was committed in particular to helping young physicians undertake additional training in an-throposophic medicine. He was exemplary in his ap-proach in the relevant working groups, passing on his great store of anthroposophic medical knowledge to his younger colleagues.

We take our farewell from a very highly esteemed col-league as he enters on retirement, and we wish him much pleasure in his new phase of life.

Our warm thanks go with him for all his work, and his commitment to the Verein für Krebsforschung.

The college of physicians at the Lukas Klinik

Farewell to: Dr. Ulrich Reichert

65

Congratulations to

01.02.2013 Fadime Pinar Domestic staff 35 years of service

01.02.2013 Christoph von Dach Director of nursing 20 years of service

01.04.2013 Iwer Helwig VfK management 20 years of service board

01.05.2013 Susanne Bornhauser Nursing 20 years of service

26.06.2013 Luis De Jesus Domestic staff/kitchen 40 years of service

01.07.2013 Hans-Richard Heiligtag Physician 30 years of service

01.10.2013 Rosa da Silva Nursing 30 years of service

18.10.2013 Stephan Baumgartner Hiscia research 20 years of service

We thank the above for all their years of loyal service.

66

A new artistic account of mistletoe by Hartmut Ramm and Jürg Buess

The newly published book by Hartmut Ramm (botanist at Hiscia Institute) and Jürg Buess (director of mistletoe processing at Hiscia Institute) most

beautifully embodies something intrinsic to the work of the Society for Can-cer Research: a preoccupation with the essential nature of mistletoe. Drawing on a store of mythological traditions and tales, along with atmospheric pho-tographs, the authors trace and delineate this inherent quality as the creative principle underlying mistletoe’s diverse forms.

“Zaubermistel – goldener Zweig“ (“Magic mistletoe – golden bough”)

Zaubermistel – Bilder und Mythen

Hartmut Ramm (Hrsg.) Jürg Buess (Fotografie)

goldener Zweig FUTURUM

67

Jürg Buess’s fascinating images give us insight into the shapes and colours of mistletoe as it develops through the year, and into the landscape of its host trees. We are granted a view of mistletoe’s relationship with the animal realm, and can see the extent to which it has emancipated itself from normal condi-tions of plant growth to become a close companion of human culture.

Hartmut Ramm has drawn on two thousand years of literary sources that testify to direct perception of mistletoe’s secrets. Amongst the oldest of these sources are passages in the Aenead by the Roman author Virgil, who still lived within the mystery stream of ancient times. Ramm also cites Druid traditions and rites connected with mistletoe, the Norse mythology of the Edda, an ancient moun-tain legend that figures in Slovenian folk wisdom, as well as two modern au-thors who give inspired accounts of mistletoe.

Hartmut Ramm has added a brief commentary to each of the seven chosen texts. Here he succeeds in conveying the quality and meaning of metaphors informing these texts. He draws attention to the archetypal images of mistle-toe that can come alive in each person’s psyche, giving him “strength, orienta-tion and courage”. The processes at work in mistletoe open up a deep source of images, revealing mistletoe to have both universal healing properties and to be a death-bringing instrument that triggered the twilight of the gods. It is found to be a key to the underworld and also one that opens up knowledge of reincarnation and karma. Opposing forces such as sun and moon, gold and sil-ver, movement and rest, fortune and misfortune, and heaven and earth, are em-bodied in mistletoe as polar attributes. The search for such archetypes, and an experience of their effect on us, are the fruits of Hartmut Ramm’s many years spent studying and cultivating mistletoe, and the regular lectures and courses he has given both to patients and the wider public.

The deep wisdom in traditional images of this kind is also apparent in the fact that the botanical and pharmacological properties of mistletoe indicated in the book find a real correspondence with these mythological texts and poems. This book exemplifies what one can truly call “belles letters” – the capacity of literature to invoke beauty. Let yourself be enchanted by the accounts of mis-tletoe contained here!

Dr. rer. nat. Konrad UrechBiologist / Research and Development

“Zaubermistel – goldener Zweig. Bilder und Mythen” Hartmut Ramm and Jürg BuessPublished by Futurum Verlag, SFr. 29.90Available in bookshops (ISBN 978-3-85636-239-3) or from the Lukas Klinik pharmacy, Arlesheim

68

We would like to remind you again of our current DVD on approaches to cancer treatment that use the mistletoe preparation Iscador. In last year’s

report we included an article on making these films, and since then the DVD has been in great demand. Below is a press review of the public showing of both films:

There was great interest. Iwer Helwig of the Verein für Krebsforschung wel-comed an audience of around 300 to the premiere of these two new publicity screenings, produced over the past year-and-a-half by Basel production com-pany Film Format. The interest was rewarded: two moving documentary films were presented rather than just ‘publicity films’ in the usual sense.

The first film conveys a sense of the diverse work accomplished at the Lukas Klinik. Director Matthias Affolter chose an outside perspective. Rather than of-fering explanations and presentations from the Lukas Klinik itself, the patients relate their experiences. In four sympathetic portraits, the film traces the un-folding process starting with the shock of cancer diagnosis through to the pa-tients’ return to daily life. The protagonists convey their anxieties and hopes, and say how they found a way to cope with their disease with the aid of ther-apies offered at the Lukas Klinik.

The second film, too – about the cancer medicine Iscador – is set in the con-text of a patient’s story, and interspersed with accounts of the origins, effect and mode of production of the medicine. The striking images of nature have great resonance, and were taken by cameraman Jonas Jäggy during mistletoe harvesting at various locations in the wild.

FilmFormat producer Mathias Hefel described his work on the project as ‘an intense experience which was both very affecting and yet enriching’ – a com-ment that relates equally to both films.

Urs Weth: Two new films describe the potential of anthroposophically extended cancer therapy at the Lukas Klinik in Switzerland, and the mistletoe preparation Iscador. In: Info3, ”Anthroposophie im Dialog“, December 2011.

The DVD with both films, Lukas Klinik – Living with cancer and Iscador – Can-cer therapy with mistletoe can be ordered free of charge from:

Verein für KrebsforschungKirschweg 9CH-4144 ArlesheimSwitzerlandTel.: +41 (0)61 706 72 72Fax: +41 (0) 61 706 72 00e-mail: sekretariat@vfk.chIt can also be viewed on the Internet at: www.lukasklinik.ch

DVD of anthroposophically extended cancer therapy

69

Bild DVD und Legende?

70

As of February 2012 (edition 5.1), documentation is available of all publica-tions relating to clinical studies on the medicine Iscador. An enlarged edi-

tion will appear as soon as the important new publication on pancreatic car-cinoma in Serbia becomes available.

The aim of this documentation is to provide a comprehensive record of all pub-lished references to clinical trials and observational studies with Iscador on the themes of immunology, DNA repair, quality of life / pain, tumour remission, survival time, safety, systematic reviews, meta-analyses and detailed case his-tories. Brief abstracts of selected studies will offer evidence of Iscador’s clini-cal and pharmacological efficacy.

Currently, to the beginning of 2012, over 65 clinical trials and observational studies have been carried out with Iscador, along with 13 systematic reviews and 2 meta-analyses of such studies. Several studies are still underway or in planning. The latest updated version of the documentation is available online.

While the studies and trials on Iscador are of varying quality, their evaluation shows a clinically relevant benefit for Iscador treatment as regards extending life expectancy and enhancing quality of life. Good tolerance and a high level of safety are also demonstrated.

Dr. rer. nat. Renatus ZieglerClinical Research and Quality Assurance

Documentation of published clinical studies on Iscador

ReferenceRenatus Ziegler / Konrad Urech, Documentation of published clinical studies with Iscador, Arlesheim: Society for Cancer Research 2012 (edition 5.1, updated: February 2012, English and German). Website: www.vfk.ch/forschung/klinische_forschung/dokumentation

7171

Literature on mistletoe and Iscador therapy

The following chronological bibliography is ordered according to specialist fields.

This is inevitably a limited selection from the great quantity of published findings. In studies marked as Review, and in the section “Systematic Reviews and Surveys of Mistletoe Therapy” summaries and further reading references are to be found. Complete documentation of published clinical studies on Iscador, which comprises all published references to clinical trials and observation studies on Iscador, can be found on our website (http://dokumentation.vfk.ch). This contains publications on the theme of immunology, DNA repair, quality of life/pain, tumour remission, survival time, safety, systematic reviews, meta-analyses and detailed case histories. Brief summaries of selected studies give insight into the corresponding clinical and pharmacological efficacy of Iscador.

Mistletoe botany

Tubeuf K.V. (Review) Monographie der Mistel. Verlag Oldenbourg, München, Berlin, 1923

Grazi G., Urech K. Einige morphologische Merkmale der Mistelbeere (Viscum album L.) und deren taxonomische Bedeutung. Beitr. Biol. Pflanzen 56, 293–306, 1981

Sallé G. Germination and establishment of Viscum album L. In: The Biology of Mistletoe; Calder M., Bernhardt P. (eds.), Academic Press, 145–159, 1983

Grazi G., Zemp M. Genista cinerea DC., ein natürlicher Sammelwirt für Viscum album ssp. album und Viscum album ssp. austriacum. Vollmann, Wiesbaden. Ber. Dtsch. Bot. Ges. 99, 99–103, 1986

Sallé G. Bases structurales et biochimiques de la résistance au gui dans le genre Populus. Acta Bot. Gall. 140 (6), 633–648, 1993

Urech K., Ramm H. Die Polarität der Mistel. Merkurstab 50 (3), 157–168, 1997

Ramm H. Zur Entwicklung der weissbeerigen Mistel (Viscum album L.): Bildung des Haustorialsystems. Mistilteinn (1), 2–13, 2000

Ramm H., Urech K., Scheibler M., et al.

Cultivation and development of Viscum album L. In: Mistletoe – The Genus Viscum. Büssing A. (ed.), Harwood Academic Publishers, Amsterdam, 75–94, 2000

Ramm H. Zur Entwicklung der weissbeerigen Mistel (Viscum album L.): Bildeprozesse im Mistelspross. Mistilteinn (2), 2–11, 2001

Ramm H. Zur Entwicklung der weissbeerigen Mistel (Viscum album L.): Bildeprozesse in Blüte, Frucht und Same. Mistilteinn (3), 32–41, 2002

Baumgartner S.M., Flückiger H., Ramm H.

Mistelbeerenform und Tierkreis. Elemente der Naturwissenschaft 79 (2), 2–20, 2003

Zuber D. (Review) Biological flora of Central Europe: Viscum album L. Flora 199, 181–203, 2004

Ramm H. Mangan – ein wichtiges Spurenelement für Eiche und Eichenmistel. Mistilteinn (8), 58–67, 2008

Urech K. Misteltragende Eichen – Häufigkeit und geographische Verbreitung in Frankreich. Mistilteinn (8), 28–39, 2008

Urech K., Jäggy C., Schaller G.

Räumliche und zeitliche Dynamik der Viscotoxin- und Mistellektingehalte in der Mistel (VISCUM ALBUM L.). In: Die Mistel in der Tumortherapie 2 – Aktueller Stand der Forschung und klinische Anwendung. R. Scheer, et al. (Hrsg.). KVC Verlag, 67–78, 2009

Ramm H. Zum Einfluss von Bodenverhältnissen auf die Kultivierung der Eichenmistel ( VISCUM ALBUM auf QUERCUS ROBUR und PETRAEA) sowie auf wirtsspezifische Mineral-stoffverhältnisse in pharmazeutischen Mistelextrakten. In: Die Mistel in der Tumor-therapie – aktueller Stand der Forschung und klinische Anwendung. Scheer R. et al. (Hrsg.), KVC Verlag Essen, 31–40, 2009

Urech K. „In Kälte erstarren“ und „in Schönheit vergehen“ – Eine Studie zur Giftwirkung der Mistel. Mistilteinn – Beiträge zur Mistelforschung 9, 26–45, 2011

72

Biological effects /active constituents

Selawry O.S., Vester F., Mai W., et al.

Zur Kenntnis der Inhaltsstoffe von Viscum album, II. Mitteilung: Tumorhemmende Inhaltsstoffe. Hoppe-Seyler’s Z. physiol. Chem. 324, 262–281, 1961

Zschiesche W. Die Wirkung von Iscador auf die Phagocytoseaktivität des reticulohistiocytären Systems. Monatsber. d. Deutschen Akademie der Wissenschaften 8 (10), 750–754, 1966

Vester F., Seel A., Stoll M., Müller J.M.

Zur Kenntnis der Inhaltsstoffe von Viscum album, III: Isolierung und Reinigung cancerostatischer Proteinfraktionen. Hoppe-Seyler’s Z. physiol. Chem. 349, 125–147, 1968

Franz H. Mistletoe lectins and their A and B chains. Oncology 43 (suppl. 1), 23–34, 1968 (neu 1986)

Vester F., Nienhaus J. Thymusstimulation and cancer prophylaxis by Viscum proteins. Experientia 26/5, 1970

Ziska P., Franz H., Kindt A.

The lectins from Viscum album L. purification by biospecific affinity chromatography. Experientia 34, 123, 1976

Vester F. Über die kanzerostatischen und immunogenen Eigenschaften von Mistelproteinen. Krebsgeschehen 5, 1977

Stirpe F., et al. Inhibition of protein synthesis by a toxic lectin from Viscum album L. (mistletoe). Biochem. J. 843–845, 1980

Franz H. Inhaltsstoffe der Mistel (Viscum album L.) als potentielle Arzneimittel. Pharmazie 40, 97–104, 1985

Ribéreau-Gayon G., et al. Effects of mistletoe (Viscum album L.) extracts on cultured tumor cells. Experientia 42, 594–599, 1986

Holtskog R., Sandvig K., Olsnes S.

Characterization of a toxic lectin in Iscador, a mistletoe preparation with alleged cancerostatic properties. Oncology 45, 172–179, 1988

Ribéreau-Gayon G., Jung M.L., Beck J.P.

Die Proteine, Alkaloide und Polysaccharide der Mistel (Viscum album L.). Therapeutikon (3) 1, 22–26, 1989 (auch auf Französisch)

Jung M.-L., Baudino S., Ribéreau-Gayon G., Beck J.P.

Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer letters 103–108, 1990

Urech K., Schaller G., Ziska P., et al.

Comparative study on the cytotoxic effect of viscotoxin and mistletoe lectin on tumour cells in culture. Phytotherapy Research, 9 (1), 49–55, 1995

Jäggy C., Musielski H., Urech K., et al.

Quantitative determination of lectins in mistletoe preparations. Arzneimittel-Forschung / Drug Research 45(2), 8, 1–5, 1995

Schaller G., Urech K., Giannattasio M.

Cytotoxicity of different viscotoxins and extracts from the European subspecies of Viscum album L. Phytotherapy Research, 10 (6), 473–477, 1996

Orrù S., Scaloni A., Giannattasio M., et al.

Amino acid sequence. S–S bridge arrangement and distribution in plant tissues of thionins from Viscum album. Biol. Chem., 378, 989–996, 1997

Schaller G., Urech K., Grazi G., et al.

Viscotoxin composition of the three European subspecies of Viscum album L. Planta Medica, 64, 677–678, 1998

Büssing A., Schaller G., Pfüller U.

Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L. Anticancer Research 18 (6A), 4291–4296, 1998

Büssing A., Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Research 19, 23–28, 1999

Büssing A. (ed.) (Review) Mistletoe – The Genus Viscum. Harwood Academic Publishers, Amsterdam, 2000

Hajto T., Berki T., Boldizsar F., et al.

Galactoside-specific plant lectin, Viscum album agglutinin-I induces enhanced proliferation and apoptosis of murine thymocytes in vivo. Immunology Letters 86, 23–27, 2003

Kelter G., Fiebig H.H. Ausschluss einer Tumorstimulation durch Iscador Präparate in vitro in einem Panel von 26 humanen Tumorzelllinien. In: Fortschritte der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. Scheer R., et al. (Hrsg.). KVC Verlag Essen, 291–302, 2005

73

Urech K., Scher J.M., Hostanska K., et al.

Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album L. Journal of Pharmacy and Pharmacology 57, 101–109, 2005

Knöpfl F., Viviani A., Rist L., et al.

Human cancer cells exhibit in vitro individual receptiveness towards different mistletoe extracts. Pharmazie 60 (6), 448–, 2005

Eggenschwiler J., Patrignani A., Wagner U., et al.

Gene expression profiles of different breast cancer cells compared with their responsiveness to fermented mistletoe (Viscum album L.) extracts Iscador from Oak (Quercus), Pine (Pinus), White Fir (Abies), and Apple Tree (Malus) in vitro. Arzneimittel-Forschung / Drug Research 56 (6a), 483–496, 2006

Kovacs E., Link S., Toffol-Schmidt U.

Cytostatic and cytocidal effects of mistletoe (Viscum album L.) Quercus extract Iscador. Arzneimittel-Forschung / Drug Research 56 (6a), 467–473, 2006

Urech K., Büssing A., Thalmann G., et al.

Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines. Anticancer Research 26 (4B), 3049–3055, 2006

Urech K., Schaller G., Jäggy C.

Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador – Analytical results on pharmaceutical processing of mistletoe. Arzneimittel-Forschung / Drug Research 56 (6a), 428–434, 2006

Elluru S.R., Huyen van J.P.D., Delignat S., et al.

Induction of maturation and activation of human dendritic cells: A mechanism underlying the beneficial effect of VISCUM ALBUM as complimentary therapy in cancer. BMC Cancer 8, 161–169, 2008

Elluru S.R., Huyen J.P., Delignat S., Prost F. et al.

Antiangiogenic properties of VISCUM ALBUM extracts are associated with endothelial cytotoxicity. Anticancer Research 29(8), 2945–2950, 2009

Kovacs E. Investigation of the proliferation, apoptosis/necrosis, and cell cycle phases in several human multiple myeloma cell lines. Comparison of VISCUM ALBUM QuFrF extract with vincristine in an in vitro model. The Scientific World Journal 10, 311-320, 2010

Immune modulation (in vitro and clinical)

Rentea R., et al. Biologic properties of Iscador: A Viscum album preparation. 1. Hyperplasia of the thymic cortex and accelerated regeneration of hematopoietic cells following X-irradiation. Laboratory investigation, 44 (1), 43–48, 1981

Bloksma M., et al. Stimulation of humoral and cellular immunity by Viscum preparations. Planta medica, 46 (4), 1982

Salzer G. Pleura carcinosis. Cytomorphological findings with the mistletoe preparation Iscador and other pharmaceuticals. Oncology 43, supp. 1, 66–70, 1986

Hajto T., Lanzrein Ch. Natural Killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology 43, 93–97, 1986

Hajto T., Hostanska K., Gabius H.J.

Modulatory Potency of the β-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Research 49, 4803–4808, 1989

Hajto T., Hostanska K., Gabius H.-J., et al.

Increased secretion of tumor necrosis factor, interleukin-1 and interleukin-6 by human mononuclear cells exposed to β-galactose-specific lectin from clinically applied mistletoe extract. Cancer Research 50, 3322–3326, 1990

Müller E.A., Anderer F.A. Chemical specificity of effector cell/tumor cell bridging by a Viscum album rhamno-galacturonan enhancing cytotoxicity of human NK cells. Immunopharmacology 19 (1), 69–77, 1990

Hajto T., Hostanska K., et al.

Antitumorale Aktivität des immunomodulatorisch wirkenden Beta-galaktosidspezi-fischen Mistellektins bei der klinischen Anwendung von Mistelextrakten (Iscador). Dtsch. Zschr. Onkol. 23 (1), 1–6, 1991

Lukyanova E.M., et al. Die Behandlung immunsupprimierter Kinder nach dem Tschernobyl-Unfall mit Viscum album (Iscador): klinische und immunologische Untersuchungen. Forschende Komplementärmedizin 1 (2), 58–70, 1994

Steinmass M., Anderer A. Enhancement of human NK and LAK cytotoxicity against HCMV infected cells by rhamnogalacturonan: Specificity of reaction. Viral Immunology 9 (1), 27–34, 1996

74

Stein G.N., Meink H., Durst J., et al.

Release of cytokines by a fermented Lectin-I (ML-I) free mistletoe extract reflects differences in the reactivity of PBMC in healthy and allergic individuals and tumor patients. Eur. J. Clin. Pharmacol. 151 (3–4), 247–252, 1996

Chernyshov V.P., et al. Immunomodulatory actions of Viscum album (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. Complementary Therapies in Medicine 5, 141–146, 1997

Nikolai G., Friedl P., Werner M., et al.

Effect of a mistletoe extract (Iscador Qu FrF) on viability and migratory behaviour of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices. In Vitro Cell Dev. Biol. – Animal 33, 710–716, 1997

Albonico H.U., Bräker H.U., Hüsler J.

Febrile infectious childhood diseases in the history of cancer patients and matched controls. Medical Hypotheses 51, 315–320, 1998

Gorter R.W., van Wely M., Stoss M., et al.

Subcutaneous infiltrates induced by injection of mistletoe extracts (Iscador). American Journal of Therapeutics 5 (3), 181–187, 1998

Stein G.M., Berg P.A. Flow cytometric analyses of the specific activation of peripheral blood mononuclear cells from healthy donors after in vitro stimulation with a fermented mistletoe extract and mistletoe lectins. European Journal of Cancer 34 (7), 1105–1110, 1998

Stein G.M., Schaller G., Pfüller U., et al.

Thionins from Viscum album L.: Influence of the viscotoxins on the activation of granulocytes. Anticancer Research 19, 1037–1042, 1999

Huber R., Klein R., Lüdtke R., Werner M.

Häufigkeit grippaler Infekte bei Gesunden unter Gabe eines lektinreichen und eines lektinarmen Mistelpräparats im Rahmen einer randomisierten, doppelblinden, placebokontrollierten Studie. Forschung Komplementärmedizin Naturheilkunde 8, 354–358, 2001

Tusenius K.J., Spoek J.M., Kramers C.W.

Iscador Qu for chronic hepatitis C: An exploratory study. Complementary Therapies in Medicine 9 (1), 12–16, 2001

Kuehn J.J., Fornalski M. Non-Hodgkin-Lymphom – Immunologische Spekulation und klinische Realität. Der Merkurstab 54 (5), 289–296, 2001

Klein R., Classen K., Berg P.A., et al.

In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. Eur. J. Med. Research 7, 1–9, 2002

Kovacs E., Kuehn J.J. Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does Viscum album treatment effect these parameters? Biomed Pharmacother 56, 152–158, 2002

Kovacs E. Effects of Viscum album extract therapy in patients with cancer. Relation with Interleukin-6, soluble Interleukin-6 receptor, and soluble gp130. The Journal of Alternative and Complementary Medicine 10 (2), 241–246, 2004

Huber R., Rostock M., Goedl R., et al.

Mistletoe treatment induces GM-CSF and IL-5 production by PBMC and increases blood granulocyte- and cosinophil counts: a placebo controlled randomized study in healthy subjects. Eur. J. Med. Research 10 (10), 411–418, 2005

Wispler M.J., Kappler M., Soto-Vera D., et al.

Prospektive, randomisierte, kontrollierte Studie zur Aktivierung des Homings und des allgemeinen Aktivitätsniveaus von T-Lymphocyten durch subkutane Mistel-extrakt-Injektionen bei gesunden männlichen Probanden. In: Fortschritte der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. Scheer R., et al. (Hrsg.). KVC Verlag Essen, 513–525, 2005

Büssing A. Immune modulation using mistletoe (Viscum album L.) extracts Iscador – Influencing cell function through subcutaneous and intravenous application. Arzneimittel-Forschung/Drug Research 56 (6a), 508–515, 2006

Elluru S., Huyen van J.P., Delignat S., et al.

Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittel-Forschung/Drug Research 56 (6a), 461–466, 2006

Huber R., Rostock M., Goedl R., et al.

Immunologic effects of mistletoe lectins: A placebo-controlled study in healthy subjects. J. Soc. Integrative Oncology 4 (1), 3–7, 2006

Schink M., et al. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. A randomized phase III trial. In: Forschung Komplementärmedizin; 17: 9–17, 2007

Gardin N.E. Immunological response to mistletoe (VISCUM ALBUM L.) in cancer patients: a four-case series. Phytother.Res. 23, 407–411, 2009

75

Klein R. Effekt von Mistelextrakten auf immunkompetente Zellen in vitro und in vivo. In: Die Mistel in der Tumortherapie 2 – aktueller Stand der Forschung und klinische Anwendung. Scheer R. et al. (Hrsg.), KVC Verlag Essen, 185–201, 2009

Schink M., Tröger W., Goyert A.

Einfluss perioperativer Mistelextrakt-Infusionen auf eine operations- und narkose-bedingte Immunsuppression bei Patienten mit kolorektalem Karzinom. In: Die Mistel in der Tumortherapie 2 – aktueller Stand der Forschung und klinische Anwendung. Scheer R. et al. (Hrsg.), KVC Verlag Essen, 441–453, 2009

Elluru S., Huyen van J.P.D., Wootla B., et al.

Tumor regressive effects of Viscum album preparations – exploration of immuno-modulatory mechanisms. Medicina (Buenos Aires) 67 (Supl. II), 85–89, 2007

Braedel-Ruoff S. Immunomodulatory effects of VISCUM ALBUM extracts on natural killer cells: Review of clinical trials. Forschende Komplementärmedizin 17, 63–73, 2010

Protective effects

Rentea R., et al. Biologic properties of Iscador: a Viscum album preparation. Laboratory Investigation 44 (1), 43–48, 1981

Kovacs E., Hajto T., Hostanska K.

Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extracts (Iscador). Eur. J. Cancer 27 (12), 1672–1676, 1991

Kuttan G. Reduction of leukopenia in mice by Viscum album administration during radiation and chemotherapy. Tumori 79 (1), 74–76, 1993

Büssing A., Lehnert A., Schink M., et al.

Effect of Viscum album L. on rapidly proliferating amniotic fluidcells. Sister chromatid exchange. Arzneimittel-Forschung/Drug Research 45 (1), 81–83, 1995

Kovacs E., Kuehn J.J., Werner M., et al.

Die Wirkung von Viscum album (Iscador) auf die DNA-Reparatur in peripheren Lymphozyten nach Gammastrahlen- und Cyclophosphamid-Exposition. Korrelation zur IFN-Gamma-Produktion. In-vitro-Ergebnisse. In: Grundlagen der Misteltherapie. Scheer R., Becker H., Berg A. (eds.). Hippokrates-Verlag, Stuttgart, p. 197–205, 1996

Kuttan G., Menon L.G., Kuttan R.

Prevention of 20-methylcholanthrene-induced sarcoma by a mistletoe extract, Iscador. Carcinogenesis 17 (5), 1107–1109, 1996

Kovacs E. The in vitro effect of Viscum album (VA) extract on DNA repair of peripheral blood mononuclear cells (PBMC) in cancer patients. Phytotherapy Research 16, 143–147, 2002

Büssing A., Bischof M., Hatzmann W., et al.

Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Research 25, 4753–4758, 2005

Schink M., Tröger W., Dabidian A., et al.

Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. A randomized phase III trial. Forschung Komplementärmedizin 17, 9–17, 2007

Burkhart J., Wälchli C., Heusser P. et al.

In vitro investigation into the potential of a mistletoe extract to alleviate adverse effects of cyclophosphamide. Alternative Therapies 16 (3), 40–48, 2010

Tröger W. Zusammenhang von Lebensqualität und Neutropenie bei Brustkrebspatientinnen, die alleine mit Chemotherapie oder zusätzlich mit Misteltherapie behandelt wurden – Ergebnisse einer randomisierten StudieDeutsche Zeitschrift für Onko logie 41, 58–67, 2011

Quality of life / pain relief

Dold U., et al. Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. G. Thieme Verlag, Stuttgart, New York, 1991

Clover A., et al. Complementary cancer therapy: a pilot study of patients, therapies and quality of life. Complementary Therapies in Medicine 3, 129–133, 1995

76

Borrelli E. Valutazione della qualità di vita in pazienti affette da adenocarcinoma mammario sottoposte a terapia con Viscum album. La Medicina Biologica, 27–30, luglio–settembre, 1999

Grossarth-Maticek R., Kiene H., Baumgartner S.M., Ziegler R.

Einsatz von Iscador, ein Extrakt der europäischen Mistel (Viscum album), zur Krebsbehandlung: Prospektive nicht-randomisierte und randomisierte Matched-Pair-Studien eingebettet in eine Kohortenstudie. Alternative Therapies in Health and Medicine 7 (3), 57–78, 2001 (auch auf Englisch und Französisch)

Bock P.R., Friedel W.E., Hanisch J., Karasmann M., Schneider B.

Wirksamkeit und Sicherheit der komplementären Langzeitbehandlung mit einem standardisierten Extrakt aus Europäischer Mistel (Viscum album L.) zusätzlich zur konventionellen adjuvanten onkologischen Therapie bei primärem, nicht metas-tasiertem Mammakarzinom. Arzneimittel-Forschung/Drug Research 54, No. 8, 456–466, 2004 (auch auf Englisch)

Toelg M., Reiss B., Antonu H.

Chemotherapie mit begleitender Misteltherapie – Prospektive, nicht randomisierte, offene Studie (AWB) zur Lebensqualität. CO’MED 11 (8), 18–22, 2005

Grossarth-Maticek R., Ziegler R.

Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur.J.Med. Res. 11, 485–495, 2006

Heusser P., Berger-Braun S., Bertschy M., et al.

Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits. Forschung Komplementärmedizin 13, 156–166, 2006

Grossarth-Maticek R., Ziegler R.

Wirksamkeit und Unbedenklichkeit einer Langzeitbehandlung von Melanom-patienten mit einem Mistelpräparat (Iscador). Schweiz. Zschr. GanzheitsMedizin 19 (6), 325–332, 2007

Loewe A., Kuehn J.J., Borho K., et al.

Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit. Forschung Komplementär medizin 15 (1), 22–30, 2008

Matthes H., Friedel W.E., Bock P.R.

Supportive care in pancreatic carcinoma patients treated with a fermented mistletoe (VISCUM ALBUM L.) extract. In: Die Mistel in der Tumortherapie 2 – Aktueller Stand der Forschung und klinische Anwendung. R. Scheer, et al. (Hrsg.). KVC Verlag, 551–562, 2009

Melzer J. Saller R. Lebensqualität onkologischer Patienten unter supportiver Behandlung mit VISCUM ALBUM (parenterale Mistelpräparate). Schweiz. Zeitschr. GanzheitsMedizin 21 (3), 157–161, 2009

Tröger W., Jezdic S., Zdrale Z. et al.

Quality of life and neutropenia in patients with early stage of breast cancer: A randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer: Basis and Clinical Research 3, 35–45, 2009

Wode K., Schneider T., Lundberg I., Kienle G.S.

Mistletoe treatment in cancer-related fatigue: a case report. Cases Journal 2 (1), 77–84, 2009

Kienle G., Kiene H. Influence of VISCUM ALBUM L (European Mistletoe) extracts on quality of life in cancer patients: A systematic review of controlled clinical studies. Integrative Cancer Therapies 9 (2), 142–157, 2010

Matthes H., Friedel W., Bock P., Zänker K.

Molecular mistletoe therapy: Friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Current Molecular Medicine 10 (4), 430–439, 2010

Büssing A., Raak C., Ostermann T.

Quality of life and related dimensions in cancer patients treated with mistletoe extract (Iscador): Meta-analysis. Evidence-based Complementary and Alternative Medicine Volume 2012, 8, 2011

Tumour remission

Leroi R. Viscum album therapy of cancer. The British Homoeopathic Journal 67 (3), 167–184, 1978

Bradley G.W., Clover A. Apparent response of small cell lung cancer to an extract of mistletoe and homoeo-pathic treatment. Thorax 44, 1047–1048, 1989

77

Hajto T., Hostanska K., Fornalski M., Kirsch A.

Antitumorale Aktivität des immunmodulatorisch wirkenden Beta-galaktosidspezi-fischen Mistellektins bei der klinischen Anwendung von Mistelextrakten (Iscador®). Deutsche Zeitschrift für Onkologie 23 (1), 1–6, 1992

Wagner R.F. Iscador M 5 mg spezial und Iscador Qu 5 mg spezial – Eine Praxisbeobachtung 1993–1996. Iscador Informationen, Heft 4, 3–42, insbesondere S. 5–7, 26–27, 1996

Wagner R.F. Ovarial Ca und Misteltherapie. Der Merkurstab 49 (2), 152–153, 1996

Kuehn J.J. Langfristig guter Verlauf unter Misteltherapie bei einem Patienten mit einem zentroblastisch-zentrosytischen Non-Hodgkin-Lymphom. Deutsche Medizinische Wochenschrift 124 (47), 1414–1418, 1999

Kuehn J.J. (Erwiderung auf Leserbriefe zu Kuehn 1999) Deutsche Medizinische Wochenschrift 125 (31–32), 958–960, 2000

Grossarth-Maticek R., Ziegler R.

Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador®). Forschung Komplementärmedizin 14 (3), 140–147, 2007

Grossarth-Maticek R., Ziegler R.

Wirksamkeit und Unbedenklichkeit einer Langzeitbehandlung von Melanom-patienten mit einem Mistelpräparat (Iscador). Schweiz. Zschr. GanzheitsMedizin 19 (6), 325–332, 2007

Kirsch A. Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador M). J. Alternative and Complementary Med. 13 (4), 443–445, 2007

Kuehn J.J. Treatment responses to Viscum album pini (Iscador P) in non-hodkin’s lymphoma – exploring a new therapeutic route. Medicina (Buenos Aires), 67 (Supl. II), 107–114, 2007

Kuehn J.J. VISCUM ALBUM L. PINI in der Behandlung des Non-Hodgkin-Lymphoms – Wirk-samkeit und Risikoeinschätzung einer subkutanen Misteltherapie im Rahmen einer retrospektiven Fallkontrollstudie. In: Die Mistel in der Tumortherapie 2 – Aktueller Stand der Forschung und klinische Anwendung. R. Scheer, et al. (Hrsg.). KVC Verlag, 353–374, 2009

Urech K. Neue Mistelpräparate auf Grundlage der «leimartigen Substanz» – Erfolge bei der Behandlung des«weissen Hautkrebses». Bericht Verein für Krebsforschung, Arlesheim, 10–14, 2009

Ritter P.R., Tischoff I., Uhl W. et al.

Sustained partial remission of metastatic pancreatic cancer following systemic chemotherapy with gemcitabine and oxaliplatin plus adjunctive treatment with mistletoe extract. Onkologie 33 (11), 617–619, 2010

Kirsch A., Hajto T. Case Reports of Sarcoma patients with optimized lectin-oriented mistletoe extract therapy. The Journal of Alternative and Complementary Medicine 17 (10), 973–979, 2011

Studies of survival periods in relation to diverse tumour locations

Faber W. Hypernephrombehandlung mit Iscador. Beitr. Erw. Heilk. 15 (2), 46–51, 1962

Majewsky A., Bentele W. Über Zusatzbehandlung beim weiblichen Genitalkarzinom. Zentralblatt für Gynäkologie 85 (20), 696–700, 1963

Fellmer C., Fellmer K.E. Nachbehandlung bestrahlter Genitalkarzinome mit dem Viscum album-Präparat Iscador. Krebsarzt 21 (3), 174–185, 1966

Fellmer K.E. A clinical trial of Iscador. British Homoeopathic Journal 57 (1), 43–47, 1968

Leroi R. Beobachtungen über die zusätzliche Iscador-Therapie in der Behandlung der Frauen mit operiertem und bestrahltem Genitalkarzinom. Gynaecologia 167 (3), 158–170, 1969

Leroi R. Malignomtherapie mit neuen Iscadorpräparaten. Krebsgeschehen 7 (5), 124–126, 1975

Leroi R. Nachbehandlung des operierten Mammakarzinoms mit Viscum album. Helv. chir. Acta 44, 403–414, 1977

78

Salzer G., Havelec L. Rezidivprophylaxe bei operierten Bronchuskarzinom-Patienten mit dem Mistel-präparat Iscador – Ergebnisse eines klinischen Versuchs aus den Jahren 1969–1971. Onkologie 1 (6), 264–267, 1978

Hoffmann J. Die Iscador-Behandlung bei Lebermetastasen. Krebsgeschehen (6), 172–175, 1979

Hassauer W., Gutsch J., Burkhardt R.

Welche Erfolgsaussichten bietet die Iscador-Therapie beim fortgeschrittenen Ovarial karzinom? Onkologie 2 (1), 28–36, 1979

Leroi R. Die Iscador-Behandlung bei inoperablen kolorektalen Tumoren. Krebsgeschehen 11 (6), 163–165, 1979

Hoffmann J. Behandlungsergebnisse bei den Blasenkarzinomen der Lukas Klinik, Schriftenreihe Krebsgeschehen. Band 16. Verlag für Medizin Dr. E. Fischer, Heidelberg, 172–175, 1980

Leroi R., Henzi M. Iscadorbehandlung von Knochentumoren. Krebsgeschehen 12 (4), 77–80, 1980

Szöts I., Tóth T. Beitrag zur Iscador-Behandlung von malignen Thoraxtumoren im Kindesalter. Krebsgeschehen 13 (1), 16–18, 1981

Leroi R., Hajto T. Die Iscador-Therapie beim Ovarialkarzinom. Krebsgeschehen 14 (2), 38–40, 1982

Hoffmann J., Hajto T. Iscadorbehandlung beim metastasierenden Mammakarzinom. Krebsgeschehen (3), 71–75, 1982

Salzer G., Havelec L. Adjuvante Iscadorbehandlung nach operiertem Magenkarzinom. Ergebnisse einer randomisierten Studie. Krebsgeschehen 15 (4), 106–110, 1983

Szöts I., Tóth T. Rezidiv eines operierten Neuroblastoms im Säuglingsalter und 2. Operation. Krebsgeschehen 15 (5), 127–128, 1983

Salzer G. Ergebnisse onkologischer Behandlungsversuche bei Lebermetastasen. Krebs geschehen (2), 46–51, 1984

Leroi R. Kasuistisches zur Iscadortherapie bei Lungenmalignomen. Krebsgeschehen 18 (2), 52–57, 1986

Salzer G. Prospektiv randomisierte Studie: Operiertes Magenkarzinom, Adjuvante Behandlung mit Iscador – eine unkonventionelle Betrachtung. Onkologie 20 (4), 90–93, 1988

Kjaer M. Mistletoe (Iscador) therapy in stage IV renal adenocarcinoma. A phase II study in patients with measurable lung metastases. Acta Oncologia 28 (4), 489–494, 1989

Salzer G., Popp W. Die lokale Iscador-Behandlung der Pleurakarzinose. In: Krebs und Alternativmedizin (II). Jungi W.F., Senn H.J. (Hrsg.). Springer Verlag Berlin, Heidelberg, 36–49, 1990

Schuppli R. Die adjuvante Behandlung des malignen Melanoms mit Iscador c Hg. In: Jungi W.F., Senn H.J. (Hrsg.), Krebs und Alternativmedizin, Springer Verlag Berlin, Heidelberg, 50–53, 1990

Salzer G., Danmayr E., Wutzlhofer F., Frey S.

Adjuvante Iscador-Behandlung operierter nicht-kleinzelliger Bronchuskarzinome. Ergebnisse einer randomisierten Studie. Onkologie 23 (4), 93–98, 1991

Dold U., et al. Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Multizentrische kontrollierte Studie zur Prüfung der Wirksamkeit von Iscador und Polyerga. Stuttgart, New York: G. Thieme, 1991

Salzer G., Hellan J., Danmayr E., et al.

Das operierte kolorektale Karzinom – Eine retrospektive Therapieanalyse. Deutsche Zeitschrift für Onkologie 24 (4), 103–107, 1992

Hoffmann J. Stellungnahme zur Bronchuskarzinom-Studie. Die Heilkunst 105 (11), 452–454, 1992

Hellan J., Danmayr E., Hellan M.

Stellenwert der Komplementärmedizin in der Behandlung onkologischer Patienten – dargestellt anhand des kolorektalen Karzinoms. Dtsch. Zschr. Onkol. 27 (4), 85–94, 1995

Portalupi E. Neoadjuvant treatment in HPV-related CIN with a mistletoe preparation (Iscador). Interner Forschungsbericht, Università degli studi di Pavia, 2005

Schaefermeyer H. Zur Therapie des Blasenkarzinoms. Der Merkurstab 49 (3), 229–233, 1996

Wagner R. Ovarial-Karzinom und Misteltherapie. Der Merkurstab 49 (2), 152f., 1996

Schaefermeyer G., Schaefermeyer H.

Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986–1996. Complementary Therapies in Medicine 6 (4), 172–177, 1998

79

Kuehn J.J. Langfristig guter Verlauf unter Misteltherapie bei einem Patienten mit einem zentroblastisch-zentrozystischen Non-Hodgkin-Lymphom. Dtsch. med. Wschr. 124, 1414–1418, 1999

Wagner R. Mammakarzinom und ISCADOR. Leitfaden für eine qualifizierte Misteltherapie. Stuttgart, Berlin: Verlag J.M. Meyer, 2007

Stumpf C., et al. Therapie mit Mistelextrakten bei malignen hämatologischen und lymphatischen Erkrankungen – eine monozentrische retrospektive Analyse über 16 Jahre. In: Forschende Komplementärmedizin 7, 139–146, 2000

Grossarth-Maticek R., Kiene H., Baum-gartner S.M., Ziegler R.

Einsatz von Iscador, ein Extrakt der europäischen Mistel (Viscum album), zur Krebsbehandlung: Prospektive nicht randomisierte und randomisierte Matched-Pair-Studien eingebettet in eine Kohortenstudie. Alternative Therapies in Health and Medicine 7 (3), 57–78, 2001 (auch auf Englisch und Französisch)

Grossarth-Maticek R., Kiene H., Baum-gartner S.M., Ziegler R.

Verlängerung der Überlebenszeit von Krebspatienten unter Misteltherapie (Iscador); Ergebnisse einer epidemiologischen Langzeitstudie. Zschr. GanzheitsMedizin 13 (4), 217–225, 2001

Wagner R. Prostatakrebs und Iscador. Verlag Meyer, Stuttgart, Berlin, 2002

Grossarth-Maticek R., Kiene H., Baum-gartner S.M., Ziegler R.

Synergieeffekte von Selbstregulation und Misteltherapie (Iscador) auf die Über lebenszeit bei Krebspatienten. Zschr. GanzheitsMedizin 16 (2), 81–89, 2004

Bock P.R., Friedel W.E., Hanisch J., et al.

Wirksamkeit und Sicherheit der komplementären Langzeitbehandlung mit einem standardisierten Extrakt aus Europäischer Mistel (Viscum album L.) zusätzlich zur konventionellen adjuvanten onkologischen Therapie bei primärem, nicht metastasiertem Mammakarzinom. Ergebnisse einer multizentrischen, komparativen, retrolektiven, epidemiologischen Kohortenstudie in Deutschland und der Schweiz. Arzneimittel-Forschung / Drug Research 54 (8), 456–466, 2004 (auch in Englisch)

Grossarth-Maticek R., Ziegler R.

Randomisierte Kohortenstudien im Matched-Pair-Design zur Misteltherapie (Iscador) bei gynäkologischen Karzinomen. In: Scheer R., Bauer R., Becker H., Fintelmann V., Kemper F.H., Schilcher H. (Hrsg.). Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag 2005, 611–623, 2005

Augustin M., Bock P.R., Hanisch J., et al.

Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract: Results from a multi-center, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittel-Forschung / Drug Research 55 (1), 38–49, 2005

Kuehn J.J. Misteltherapie bei malignen Lymphomen – Neue Erkenntnisse und Erfahrungen im Rahmen einer prospektiven Kasuistikserie bei Patienten mit follikulärem Non-Hodgkin-Lymphom. In: Fortschritte der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. Scheer R., et al. (Hrsg.). KVC Verlag Essen, 477–489, 2005

Stumpf C., Rieger S., Schietzel M.

Retrospektive Untersuchung zur Therapie mit Mistelextrakten bei Mammakarzinom. Dtsch. Zschr. Onkol. 37, 106–113, 2005

Bar-Sela G., Goldberg H., Beck D., et al.

Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. Anticancer Research 26 (1), 709–713, 2006

Girke M. Lymphoplasmozytoides Immunocytom. Merkurstab 59 (2), 149–152, 2006

Grossarth-Maticek R., Ziegler R.

Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): A re-analysis. Eur. J. Med. Research 11, 485–495, 2006

Kröz M., Girke M., Brauer D.

Multidimensionale Erfassung des Krankheitsverlaufes eines Patienten mit Pleurames otheliom unter Misteltherapie. In: Onkologie, Fintelmann V. (Hrsg.), Kapitel 7.1.1.4, 1–12, 2006

Kuehn J.J. Ergebnisse bei der Behandlung von malignen Lymphomen mit dem Mistelpräparat Iscador. in: Ethik und Wissenschaft in der anthroposophischen Medizin. E. Streit, L. Rist (Hrsg.). Peter Lang AG, Intern. Verlag der Wissenschaften, Bern, pp. 85–94, 2006

80

Grossarth-Maticek R., Ziegler R.

Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur. J. Med. Research 13, 107–120, 2008

Friedel E., Matthes H., Bock P.R., Zänker K.

Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in non-metastatic colorectal carcinoma: mulitcenter, controlled, observational cohort study. Journal of the Society for Integrative Oncology 7(4), 1–10, 2009

Kienle G., Glockmann A., Schink M., Kiene H.

VISCUM ALBUM L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. Journal of Experimental & Clinical Cancer Research 29, 79–112, 2009

Longhi A., Mariani E., Kuehn J.J.

A randomized study with adjuvant mistletoe versus oral etoposide on post relapse disease-free survival in osteosarcoma patients. European Journal of Integrative Medicine 1, 27–33, 2009

Matthes H., Friedel W.E., Bock P.R.

Supportive care in pancreatic carcinoma patients treated with a fermented mistletoe (VISCUM ALBUM L.) extract. In: Die Mistel in der Tumortherapie 2 – Aktueller Stand der Forschung und klinische Anwendung. R. Scheer, et al. (Hrsg.). KVC Verlag, 551–562, 2009

Safety and lack of side effects

van Wely M., Stoss M., Gorter R.W.

Toxicity of a standardized mistletoe extract in immuno-compromised and healthy individuals. American Journal of Therapeutics 6 (1), 37–43, 1999

Gorter R.W., van Wely M., Reif M., Stoss M.

Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Alternative Therapies 5 (6), 37–48, 1999

Stein G.M., Berg P.A. Adverse effects during therapy with mistletoe extracts. In: Büssing A. (ed.), Mistletoe – The Genus Viscum. Amsterdam: Harwood Academic Publishers 2000, 195–208, 2000

Kienle G., Kiene H. Verträglichkeit, Nebenwirkungen, Überempfindlichkeitsreaktionen, Toxizität. In: Kienle G., Kiene H., Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Stuttgart: Schattauer 2003, 591–607, 2003

Bock P.R., Friedel W.E., Hanisch J., et al.

Wirksamkeit und Sicherheit der komplementären Langzeitbehandlung mit einem standardisierten Extrakt aus Europäischer Mistel (Viscum album L.) zusätzlich zur konventionellen adjuvanten onkologischen Therapie bei primärem, nicht metastasiertem Mammakarzinom. Ergebnisse einer multizentrischen, komparativen, retrolektiven, epidemiologischen Kohortenstudie in Deutschland und der Schweiz. Arzneimittel-Forschung / Drug Research 54 (8), 456–466, 2004 (auch in Englisch)

Saller R., Kramer S., Iten F., Melzer J. (Review)

Unerwünschte Wirkungen der Misteltherapie bei Tumorpatienten – Eine syste-matische Übersicht. In: Scheer R., Bauer R., Becker H., Fintelmann V., Kemper F.H., Schlicher H. (Hrsg.), Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag, 367–403, 2005

Augustin M., Bock P.R., Hanisch J., et al.

Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract: Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arznei mittel-Forschung / Drug Research 55 (1), 38–49, 2005

Kelter G., Fiebig H. Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro. Arzneimittel-Forschung / Drug Research 56 (6a), 435–440, 2006

Melzer J., Iten F., Hostanska K., Saller R.

Efficacy and safety of mistletoe preparations (VISCUM ALBUM) for patients with cancer diseases. Forschende Komplementärmedizin 16 (4), 217–226, 16–24, 2009

Kienle G., Grugel R., Kiene H.

Safety of higher dosages of Viscum album L. in animals and humans – Systematic review of immune changes and safety parameters. BMC Complementary and Alter-native Medicine, 11 (25), 2011

81

Anthroposophic background

Steiner R., Wegman I. Fundamentals of therapy. An extension of the art of healing through spiritual knowledge. Rudolf Steiner Press, 35 Park Road, London NW1

Steiner R. Anthroposophische Menschenerkenntnis und Medizin. Zwei Vorträge, Den Haag 15./16. Nov. 1923. Abdruck in Natura 5 (4), 101–117, und (5), 133–154, 1931/32

Steiner R. Richtlinien zum Verständnis für die auf anthroposophischer Geisteswissenschaft aufgebaute Heilmethode. Penmaenmawr/Wales, 28. Aug. 1923, GA 319. Rudolf Steiner Verlag, Dornach, 1964

Steiner R. Die Kunst des Heilens vom Gesichtspunkt der Geisteswissenschaft. Sechs Vorträge, London 1923/1924. GA 319. Rudolf Steiner Verlag, Dornach, 1983

Steiner R., Wegman I. Grundlegendes für eine Erweiterung der Heilkunst nach geisteswissenschaftlichen Erkenntnissen. 6. Auflage. Rudolf Steiner Verlag, Dornach, 1984

Steiner R. Geisteswissenschaft und Medizin. 13. Vortrag, Dornach, 2.4.1920, GA 312. Rudolf Steiner Verlag, Dornach, 1985

Steiner R. Physiologisch-therapeutisches auf Grundlage der Geisteswissenschaften. Elf Vorträge, Dornach, 7.10.1920 bis 22.4.1924, GA 314. Rudolf Steiner Verlag, Dornach, 1989

Husemann G. Das Tumorproblem in Pathologie und Erziehung. Anthr.-med.Jb. 1, 271–298, 1950

Leroi A. Die Bedeutung der Zelle für das Karzinom. Beitr. Erw. Heilk. 5 (3/4), 41–53, 1952

Jensen O. Zum Krebsproblem. Beitr. Erw. Heilk. 11 (7/8), 151–153, 1958

Leroi A. Rudolf Steiners Beitrag zum Krebsverständnis und zur Krebsbehandlung. Die Drei 31 (1), 20–30, 1961

Bellmann P.G., Daems W.F.

Ist die Mistel ein altes Krebsheilmittel? Sudhoffs Archiv für Geschichte der Medizin und der Naturwissenschaften 4, 1965

Leroi A. Ist der Krebs ein Zellproblem? Die Drei, 36 (5), 324–332, 1966

Fyfe A. Die Signatur des Mondes im Pflanzenreich. Kapillar-dynamische Untersuchungs-ergebnisse. Verlag Freies Geistesleben, Stuttgart, Juni 1967

Holtzapfel W. Räumliche und zeitliche Ordnung im Wachstum der malignen Tumoren. Beitr. Erw. Heilk. 20 (6), 183–194, 1967

Leroi A. Die Mistel als Tierpflanze des alten Mondes. Beitr. Erw. Heilk. 3(7/8), 153–162, 1950

Leroi A. La Terapia del cancro con vischio e i suoi fondamenti. A.M.O.S., s.r.l., via Pessano 11, I–20151 Milano

Leroi R. Iscador Therapy of inoperable colorectal carcinoma. Krebsgeschehen 11 (6), 163–165, 1979

Leroi R. Der Kiesel und seine Rolle bei Tumor und Entzündung. Beitr. Erw. Heilk. (2), 2–14, 1980

Lorenz F. Cancer – a mandate to humanity. Mercury press, Spring Valley, N.Y. USA, 1982

Fyfe A. Die Signatur des Uranus im Pflanzenreich. Verlag Freies Geistesleben, Stuttgart, 1984

Leroi A., Bühler W. Cancer as a disease of our time. Translation from «Soziale Hygiene», Merkblätter, 1985

Leroi A. Ursachen und Behandlung des Karzinoms. In: F. Husemann und O. Wolff: Das Bild eines Menschen als Grundlage der Heilkunst. 3. Band, Verlag Freies Geistes leben, Stuttgart 31, 1986

Leroi R. Die Mischung der Mistelsäfte – Angaben R. Steiners. Beitr. Erw. Heilk. (5), 238–246, 1987

Glas N. Medizinische Moral, wie sie sich einem Arzte aus der Lebenspraxis ergeben hat. Ein Buch für Ärzte, Medizin-Studierende und im Heilberuf Tätige. Hrsg: Verein für Krebsforschung Arlesheim, 1987 (CHF 15.–)

Leroi R. (ed.) (Review) Misteltherapie – eine Antwort auf die Herausforderung Krebs. Die Pioniertat Rudolf Steiners und Ita Wegmans. Verlag Freies Geistesleben, Stuttgart, 1987

82

Leroi R. Wiedergewinnung der Form durch Misteltherapie. Beitr. Erw. Heilk., Sonderheft Nov., 2–11, 1988

Leroi R. Illness and healing in the context of cosmic evolution. Temple Lodge Press, London, 1988

Heusser P. Grundsätzliches zum Verständnis der anthroposophischen Medizin und Krebs therapie. WELEDA Korrespondenzblätter für Ärzte 41 (121), 47–85, 1988

Heusser P. Malignome der Jugend und des Alters. Schweiz. Zschr. GanzheitsMedizin (5), 236–241, 1991

Ramm H. Die Mistel und ihre pharmazeutische Verarbeitung vor dem Hintergrund des Planetarischen. Merkurstab 46 (6), 541–552, 1993

Göbel T. Erdengeist und Landschaftsseele. Persephone Bd. 6, Verlag am Goetheanum, 1994

Heiligtag H.R. (ed.) Antroposophical medicine and therapies for cancer. Mercury Press, Spring Valley (NY), 1995

Ramm H. Die Mistel in der Zeit; ein Beitrag zum 75-jährigen Bestehen der anthroposo-phischen Misteltherapie. Merkurstab 48 (2), 113–123, 1995

Heusser P. Führt die Molekularbiologie zu einem neuen Konzept des Organismus? Das Beispiel der Karzinogese. Forschung Komplementärmedizin 4 (2), 106–111, 1997

Leroi R. An anthroposophical approach to cancer. Mercury (16), 30–65, 1997

Kempenich R. De la cellule à la conscience – approche anthroposophique de cancer. Collection Conscience et Santé. Ass. Patients de la Médicine d’Orientation Anthroposophique, 1999

Fintelmann V. (Review) Onkologie auf anthroposophischer Grundlage. Verlag J. Mayer, Stuttgart, Berlin, 2002

Urech K. Polarität von Leim und Schleim in der Mistel. Merkurstab 55 (1), 22–28, 2002

Ramm H. Zum Mistelkult der keltischen Druiden. Mistilteinn (4), 4–15, 2003

Baumgartner S., Flückiger H., Jäggy Ch., et al.

Untersuchungen des Iscador-Maschinenprozesses in Modellsystemen der Zytotoxi-kologie und Phytopathologie. In: Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. Scheer R., et al. (Hrsg.). KVC Verlag Essen, 169–179, 2005

Schramm H. Karzinomerkrankung und Misteltherapie. Rudolf Steiners Angaben in Beziehung zu pro- und antiinflammatorischen Reaktionen in so genannten immunologisch privilegierten Organbereichen. Merkurstab 60 (3), 229–233, 2007

Brettschneider H. Zur anthroposophischen Menschenkunde der Krebskrankheit. In: Tycho de Brahe-Jahrbuch für Goetheanismus, Tycho Brahe Verlag, Niefern-Öschelbronn, p. 105–143, 2008

Kunz C. Wirtsbäume der Mistel – Die Grundpolarität. Merkurstab 6 (2), 123–128, 2008

Schramm H. Krebs als verlagertes Sinnesorgan: die Entwicklung des Ohres und ihre Beziehung zur Karzinogenese. Der Merkurstab 63 (1), 22–28, 2010

Ramm H. Rudolf Steiner und das Wesen der Mistel. Mistilteinn – Beiträge zur Mistelforschung 9, 4–25, 2011

Schmidt D., Baumgartner S.

Eine Bildekräftebetrachtung der Mistel. Mistilteinn – Beiträge zur Mistelforschung 9, 66–87, 2011

Systematic reviews and surveys of mistletoe therapy

Franz H. (ed.) Pharmacologically relevant components of Viscum album L. Mistletoe. Oncology Supplement Dec. 1986, 43/SI/86

Leroi R. (Hrsg.) Misteltherapie – Eine Antwort auf die Herausforderung Krebs. Die Pioniertat Rudolf Steiners und Ita Wegmans. Verlag Freies Geistesleben, Stuttgart, 1987

Matthiessen P.F., Tröger W.

Die Misteltherapie des Krebses. In: Wrba H. (Hrsg.) Kombinierte Tumortherapie – Grundlagen, Möglichkeiten und Grenzen adjuvanter Methoden. Hippokrates Verlag, Stuttgart, 271–290, 1995

83

Overstolz A. Die Mistel in der Krebstherapie. Möglichkeiten einer adjuvanten Behandlung am Beispiel von Iscador. Schweiz. Zschr. Verlag für GanzheitsMedizin 10 (7/8), 352–356, 1998 (auch in Englisch, Französisch und Italienisch)

Büssing A. (Hrsg.) Mistletoe – The Genus Viscum. Medicinal and Aromatic Plants-Industrial profile. Vol. 16, Harwood Academic Publishers, 265 p., 2000

Fintelmann V. (Hrsg.) Onkologie auf anthroposophischer Grundlage. Verlag J. Mayer Stuttgart, Berlin, 2002

Kienle G.S., Berrino F., Büssing A., et al.

Mistletoe in cancer: a systematic review on controlled clinical trials. European Journal of Medical Research 8, 109–119, 2003

Schierholz J.M., Schlodder D.

Komplementäre Tumortherapie mit Mistelextrakten: eine aktuelle Übersicht. Deutsche Zeitschrift für Onkologie 35, 124–133, 2003

Kienle G.S., Kiene H. Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Stuttgart, Schattauer, 2003

Urech K., Ziegler R. Viscum album L. in der Krebs-Therapie; Botanik, Pharmakologie und neue klini sche Studien. Drogenreport 16 (29), 34–39, 2003

Overstolz A. Iscador – Mistletoe preparations in anthroposophical extended cancer treatment. Verlag für GanzheitsMedizin, 89 p., 2003 (€ 11.– + post/packing)

Overstolz A. Iscador – Mistelpräparate aus der anthroposophisch erweiterten Krebsbehandlung. Basel, Verlag für GanzheitsMedizin, zweite Auflage 2005

Horneber M.A., Bueschel G., Huber R., et al.

Mistletoe Therapy in Oncology. Cochrane Database of Systematic Reviews 2008, Issue 2 No. CD003297

Fintelmann V., Borchard U., Grebe W., et al.

Experten-Konsens. Misteltherapie in der Onkologie. Praxis Magazin 4, 48–50, 2006

Kienle G., Kiene H. Klinische Studien zur anthroposophischen Misteltherapie – Eine aktuelle Übersicht. in: Ethik und Wissenschaft in der anthroposophischen Medizin. E. Streit, L. Rist (Hrsg.), Peter Lang AG, Intern. Verlag der Wissenschaften, Bern, 115–150, 2006

Kienle G.S., Kiene H., Albonico H.U.

Anthroposophische Medizin: Health Technology Assessment Bericht – Kurzfas-sung. Forschende Komplementärmedizin 13 (2), 7–18, 2006

Kienle G.-S., Kiene H. Complementary cancer therapy: A systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur. J. Med. Research 12, 1–17, 2007

Horneber M., Büschel G., Huber R. et al.

Randomisierte kontrollierte Studie zur Misteltherapie in der Onkologie – eine systematische Übersicht. Die Mistel in der Tumortherapie 2 – aktueller Stand der Forschung und klinische Anwendung. Scheer R. et al. (Hrsg.), KVC Verlag Essen, 295–307, 2009

Kienle G., Grugel R., Kiene H.

Safety of higher dosages of Viscum album L. in animals and humans – Systematic review of immune changes and safety parameters. BMC Complementary and Alter-native Medicine, 11 (25), 2011

Reports on the treatment of malignant tumours using Viscum album(Mitteilungen aus der Behandlung maligner Tumore mit Viscum album)

Heft 1/1969, 1. Jg. Iscador-Behandlung der Genital-Karzinome I (Kopie)

Heft 2/1969, 1. Jg. Iscador-Behandlung der Genital-Karzinome II (Kopie)

Heft 3/1969, 1. Jg. Methoden zur Früherfassung der Malignome

Heft 1/1970, 2. Jg. Iscador-Behandlung des Mammakarzinoms

Heft 2/1970, 2. Jg. Iscador-Behandlung der Lympho-Granulomatose

Heft 3/1970, 2. Jg. Sonderheft zur Ernährung der Malignomkranken

Heft 2/1971, 3. Jg. Behandlung der Sarkome

Heft 3/1971, 3. Jg. Künstlerische Therapie bei Malignomkranken

84

Heft 1/1972, 4. Jg. Behandlung der Malignome des Verdauungstraktes

Heft 2/1972, 4. Jg. Behandlung der Blasen-Karzinome

Heft 3/1972, 4. Jg. Behandlung der Haut-Malignome

Heft 2/1973, 5. Jg. Leber und Karzinom

Heft 3/1973, 5. Jg. Die Metallkombinationen des Iscadors

Heft 1/1974, 6. Jg. Behandlung der Gehirntumoren (Kopie)

Heft 2/1974, 6. Jg. Die Mistel

Heft 1/1975, 7. Jg. Krebs und Psyche – Viscaceae und Loranthaceae

Heft 2/1975, 7. Jg. Zur Entstehung und Behandlung der Genital-Karzinome

Heft 3/1975, 7. Jg. Zur Entstehung und Behandlung der Genital-Karzinome

Heft 1/1976, 8. Jg. Nierenmalignome

Heft 2/1976, 8. Jg. Aus der Arbeit der Hiscia: Apis in der Krebstherapie

Heft 3/1976, 8. Jg. Chemotherapie, Kaelin-Blutsteigbild

Heft 1/1977, 9. Jg. Hodenmalignome

Heft 2+3/1977, 9. Jg. Zur Iscador-Behandlung des Mamma-Karzinoms

Heft 1/1978, 10. Jg. Zur Iscador-Behandlung des Prostatakarzinoms

Heft 2/1978, 10. Jg. Zur Iscador-Behandlung der Problem-Tumoren

Heft 3/1978, 10. Jg. Immunologie

Heft 1/1979, 11. Jg. Galle und Leber

Heft 2/1979, 11. Jg. Pankreaskarzinom – Mistelzüchtung

Heft 3/1979, 11. Jg. Neue Erkenntnisse beim Bronchuskarzinom

Heft 1/1980, 12. Jg. Krebs und Licht

Heft 3/1980, 12. Jg. Behandlung der Malignome des Verdauungstraktes

Heft 1/1981, 13. Jg. Krebs und Wärme – die Nadelholzmisteln

Heft 2/1981, 13. Jg. Behandlung des Lymphödems – Die Wirtsbäume der Laubholzmistel

Heft 3/81 bzw. 1/82 Berichte aus der Forschungsabteilung des Hauses Widar

Heft 2/1982, 14. Jg. Pleuritis carcinomatosa

Heft 3/1982, 14. Jg. Behandlung des malignen Melanoms

Heft 1/1983, 15. Jg. Nachsorge bei Patienten mit bösartigen Erkrankungen

Heft 2+3/1983, 15. Jg. Zur Iscador-Behandlung des Mammakarzinoms (erw. Auflage)

Heft 1/1984, 16. Jg. Krebs und Seele

Heft 2+3/1984, 16. Jg. Behandlung der Gehirntumoren (neue erw. Aufl.)

Heft 1/1985, 17. Jg. Blei und Silber in der Krebstherapie

Heft 2+3/1985, 17. Jg. Maligne Lymphome

Heft 1+2/1986, 18. Jg. Behandlung der Sarkome

Heft 3/1986, 18. Jg. Immunologische Wirkungen von Mistelpräparaten

Heft 1/1987, 19. Jg. Leber und Karzinom (neue erw. Aufl.)

Heft 2/1987, 19. Jg. Naturwissenschaftliche Ergebnisse: Wirkung der Mistel auf Tiertumoren

Heft 3/1987, 19. Jg. Grundsätzliches zum Verständnis der anthroposophischen Medizin und Krebstherapie

Heft 1+2/1988, 20. Jg. Iscador-Behandlung bei Patienten im Osten und andere Krankengeschichten

85

Iscador information(Iscador Informationen: This medical journal replaced the above series of “reports” which concluded in 1988) Published so far

Issue 1/1994, year 1 Zur Behandlung des Mammakarzinoms

Issue 2/1994, year 1 Die Mistel: Botanik – Morphologie – Inhaltsstoffe

Issue 3/1995, year 2 Bronchialkarzinom, Pleurakarzinose

Issue 4/1996, year 3 Iscador M 5 mg spezial, Iscador Qu 5 mg spezial – Eine Praxisbeobachtung – 1993–1996 by Dr. med. R. Wagner

Issue 5/1996, year 3 Von der Mistel zum Iscador

Issue 6/1997, year 4 Maligne Pankreastumoren und ihre Behandlung

Issue 7/1998, year 5 Zur klinischen Wirksamkeit von Iscador

Issue 8/2002 Maligne Lymphome und ihre Behandlung

Documentation Iscador – Science-based information, 2010. Disc included: Documentation of published clinical studies with Iscador (K. Urech und R. Ziegler). Ed.: Weleda Schwäbisch Gmünd (D). Available in German

Guidelines Iscador in cancer therapy. Recommendations for treatment, 2010. Ed.: Weleda Schwäbisch Gmünd (D). International edition

Annual report of the Society for Cancer Research, 1994 – today (available in German, English and French)

Nutrition S. Helwig: Tips for a healthy diet. Edition Lukas Klinik, 1998

Cookery book The Demeter Cookbook by Hermann Spindler Bound colour edition CHF 41.–/€ 25.– Clairview Books, 2009From the Lukas Klinik for patients with cancer or precancerous conditions.

Guides Krebsbehandlung und ergänzende Misteltherapie. Ein Leitfaden für Patienten und Angehörige. Hrsg.: Verein für Krebsforschung, Arlesheim 2004 (also in French)

Prospectus Injection instructions for Iscador. Ed.: Verein für Krebsforschung, Arlesheim; 2004 (also in German, French and Italian)

Information for cancer patients – focus on mistletoe therapy. Ed.: Weleda Schwäbisch Gmünd 2005 (also in German)

Eine Chance mehr bei Brustkrebs – die Krankheit ganzheitlich behandeln. Ed.: Weleda Schwäbisch Gmünd 2006

Eine Chance mehr bei Prostatakrebs – die Krankheit ganzheitlich behandeln. Ed.: Weleda Schwäbisch Gmünd, 2007

Eine Chance mehr bei Darmkrebs – die Krankheit ganzheitlich behandeln. Ed.: Weleda Schwäbisch Gmünd, 2009

A.Overstolz: Iscador – Mistletoe preparations in anthroposophical extended cancer treatment. Verlag für GanzheitsMedizin, 89 p., 2003

DVD Iscador-mistletoe therapy. From the mistletoe plant to the anti-cancer medication Iscador. Treatment with Iscador mistletoe – the first steps (both films in German and English. Since 2010 a version with french subtitles is available).

Lukas Klinik – Living with cancer / Iscador – Cancer therapy with mistletoe. Basel: FilmFormat Mathias Hefel, 2011 (both films in German and English)

86

Further literature can be found at www.hiscia.chWe also highly recommend the following websites:

www.lukasklinik.ch Homepage of the Lukas Klinik, Arlesheimwww.hiscia.ch Homepage of the institute Hiscia, Arlesheimwww.mistel-therapie.de Detailed data bank on mistletoewww.einechancemehrbeikrebs.de Weleda homepage on mistletoe and cancer www.stiftung-patientenkompetenz.org Self-help information for Germany www.patientenkompetenz.ch … and Switzerlandwww.swisscancer.ch Swiss Cancer Leaguewww.krebsgesellschaft.de German Cancer Associationwww.betacare.de List of self-help organisationswww.leben-wie-zuvor.ch Swiss association of women after breast cancerwww.stiftungpath.de The world’s only data bank run for and by tumour patients www.cancernet.nci.nih.gov National Cancer Institute in USAwww.nccam.nih.gov Dept. for complementary medicine of the US health authority www.mdanderson.org/cimer University of Texas cancer centre with very detailed information on complementary medicine

New publications 2012

Amer B., Juvik O.J., Dupont F. et al.

Novel aminoalkaloids from European mistletoe (Viscum album L.). Phytochemistry Letters 5 (3), 677–681, 2012

Bar Sela G. White-berry mistletoe (Viscum album L.) as complementary treatment in cancer: does it help? European Journal of Integrative Medicine 3, e55–e62, 2012

Bouzek T. Misteltherapie bei Patienten mit Hirntumoren: 3 Kasuistiken. Der Merkurstab 65 (3), 249–256, 2012

Brandenberger M., Simões-Wüst A.P., Rostock M. et al.

Lebensqualität von Brustkrebspatientinnen während der Misteltherapie: eine qualitative Studie. Schweiz. Zeitsch. für Ganzheitsmedizin 24 (2), 95–100, 2012

Brandenberger M., Simões-Wüst A.P., Rostock M. et al.

An exploratory study on the quality of life and individual coping of cancer patients during mistletoes therapy. Integrative Cancer Therapies 11 (2), 90–100, 2012

Delebinski C.I., Jaeger S., Kemnitz H.K. et al.

A new development of triterpene acid-containing extracts from Viscum album L. displays synergistic induction of apoptosis in acute lymphoblastic leukaemia. Cell Proliferation 45 (2), 176–187, 2012

Orange M., Lace A., Fonseca M.P. et al.

Durable regression of primary cutaneous B-cell lymphoma following fever-inducing mistletoe treatment: two case reports. Global Advances in Health and Medicine 1 (1), 18–25, 2012

Galun D., Tröger W., Reif M. et al.

Mistletoe extract therapy versus antineoplastic therapy in patients with locally advanced or metastatic pancreatic cancer: a randomized clinical phase III trial on overall survival (abstract). Annals of Oncology 23 (suppl. 9), 2012

Galun D., Tröger W., Reif M. et al.

Phase III trial on mistletoe extract versus no antineoplastic therapy in patients with locally advanced or metastatic pancreatic cancer (abstract). European Journal of Integrative Medicine 4S, 11–12, 2012

Girke M., Debus M. Kröz M.

Aszites bei Non-Hodgkin-Lymphom (V.a. splenales Lymphom): Remission nach viermaliger intraperitonealer Viscum-album-Instillation. Der Merkurstab 65 (3), 257–258, 2012

Hajto T., Fodor K., Perjési P., Németh P.

Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine. Evidence-based Complementary and Alternative Medicine, article ID 298972, 6pp., 2012

87

Hong C.E., Lyu S.Y. The antimutagenic effect of mistletoe lectin (Viscum album L. var. Coloratum ag-glutinin). Phytotherapy Research 26 (5), 787–790, 2012

Huber R., Lüdtke H., Wieber J, Beckmann C.

Safety and effects oft wo mistletoe preparations on production of Interleukin-6 and other immune parameters – a placebo controlled clinical trial in healthy subjects. BMC Complementary and Alternative Medicine 11, p. 116, 2012

Kienle G.S., Glockmann A., Grugel R. et al.

Clinical research on anthroposophic medicine: update of a health technology assessment report and status quo. Forsch. Komplementärmed. 18 (5), 269–282, 2012

Kim K.C., Yook J.H., Eisenbraun J. et al.

Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma – a randomized, controlled pilot study. BMC Com-plementary and Alternative Medicine 12 (1), 172, 2012

Kuonen R., Weissenstein U., Baumgartner S., Urech K.

Effects of Viscum album lipophilic extract and oleanolic acid on migratory activ-ity of NIH/3T3 fibroblasts (abstract). European Journal of Integrative Medicine 4 (suppl. 1), 125–126, 2012

Oenay-Uçar E., Erol O., Kandemir B. et al.

Viscum album L. extract protects HeLa cells against nuclear and mitochondrial DNA damage. Evidence-based Complementary and Alternative Medicine, article ID 958740, 7 pp., 2012

Ostermann T. Büssing A. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore 8 (5), 277–281, 2012

Sekeroglu V., Aydin B., Sekeroglu Z.A.

Viscum album L. extract and quercetin reduce cyclophosphamide-induced cardiotoxicity, urotoxicity and gentoxicity in mice. Asian Pacific Journal of Cancer Prevention 12 (11), 2925–2931, 2012

Süsskind M., Thürmann P.A., Lüke C. et al.

Adverse drug reactions in a complementary medicine hospital: a prospective, intensified surveillance study. Evidence-based Complementary and Alternative Medicine, article ID 320760, 8 pp., 2012

Strüh C.M., Jäger S., Schempp C.M. et al.

A novel triterpene extract from mistletoe induces rapid apoptosis in murine B16.F10 melanoma cells. Phytotherapy Research 26, 1507–1512, 2012

Tröger W., Zdrale Z., Stankovic N.

Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album L. extract to chemo-therapy alone. Breast Cancer: Basic and Clinical Research 6 (1), 173–180, 2012

Wilkens J., Mandera R. Die Ulmenmistel. Der Merkurstab 65 (5), 432–447, 2012

Zaenker K.S., Matthes H., Bock P.R., Hanisch J.

A specific mistletoe preparation (Iscador Qu) in colorectal cancer (CRC) patients: more than just supportive care? Journal of Cancer Science & Therapy 4 (9), 264–270, 2012

Ziegler R., Reif M., Kunz C. et al.

Anthroposophische Misteltherapie in Kliniken der Schweiz. Der Merkurstab 65 (5), 448–455, 2012

Books on mistletoe therapy

Ramm H., Buess J. Zaubermistel – goldener Zweig. Futurum Verlag, Basel, 2013

Meyer F., Straub M. Die magischen 11 der heilenden Pflanzen. Gräfe und Unzer, München 2011

Rippe et al. Die Mistel – Eine Heilpflanze für die Krankheiten unserer Zeit. Pflaum Verlag, München, 2010

Wagner R. Von der Erfahrungsheilkunde zur rationalen Therapie. Ein Leitfaden zur Mistel-therapie aus praktischer Erfahrung. Verlag J.M. Mayer, Stuttgart, Berlin, 2009

Schramm H. Heilmittel der anthroposophischen Medizin. Urban und Fischer Verlag, München, 2009

88

Scheer R., Alban S., Becker H., et al. (Hrsg.)

Die Mistel in der Tumortherapie 2. KVC Verlag Essen, 2009

Wagner R. Fragen und Antworten zur Misteltherapie. Verlag J.M. Mayer, Stuttgart, Berlin, 2007

Wagner R. Mammakarzinom und ISCADOR. Leitfaden für eine qualifizierte Misteltherapie. Verlag J.M. Mayer, Stuttgart, Berlin, 2007

Kienle G., Kiene H., Albonico H.U.

Anthroposophic Medicine, effectiveness, utility, costs, safety. Schattauer Verlag, Stuttgart, New York, pp. 351, 2006

Bopp A. Die Mistel – Heilpflanze in der Krebstherapie. Rüffer & Rub Sachbuchverlag, Zürich, 1. Auflage Dezember 2006

Wagner R. Darmkrebs und Iscador. Verlag J.M. Mayer, Stuttgart, Berlin, 2005

Scheer R., Bauer R., Becker H., et al. (Hrsg.)

Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. KVC Verlag Essen, 662 Seiten, 2005

Overstolz A. (Hrsg.) Iscador – Mistelpräparate aus der anthroposophisch erweiterten Krebsbehandlung. Verlag für GanzheitsMedizin Basel, 102 Seiten (2. Auflage), 2005

Wagner R. Krebs – den Lebensfaden wiederfinden; Psychoonkologie für Arzt und Patient. Verlag Mayer, Stuttgart, Berlin, 171 S., 2003

Kienle G., Kiene H. Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Verlag Schattauer, Stuttgart, 749 S., 2003

Wagner R. Prostatakrebs und Iscador. Ein Klinikbegleiter und Leitfaden für Diagnostik, Operation, Nachsorge und Folgetherapie. Verlag J.M. Mayer & Co., Stuttgart, Berlin, 2002

Fintelmann V. Onkologie auf anthroposophischer Grundlage. Verlag J.M. Mayer & Co., Stuttgart, Berlin, 2002

Wagner R. Iscador M/Qu spezial – Erfahrungen und Ergebnisse. Beiträge zur Krebstherapie. Verlag Urachhaus Stuttgart, 164 Seiten, 2001

Büssing A. (Hrsg.) Mistletoe – The Genus Viscum. Medical and aromatic plants – Industrial profiles. Vol. 16, Harwood Academic Publishers, 265 Seiten, 2000

Heiligtag H.R. Krebs besser verstehen. Ein Ratgeber aus der Sicht der anthroposophisch erweiterten Medizin. aethera im Verlag Freies Geistesleben & Urachhaus, Stuttgart, 1999

Glöckler M., Schürholz J. Krebsbehandlung in der anthroposophischen Medizin. Verlag Freies Geistesleben, Stuttgart 1996

Goebel T. Erdengeist und Landschaftsseele; Gestaltwirkungen geistiger Wesen im Pflanzenreich und in der Mistel. Persephone, Arb.berichte der Med.Sektion am Goetheanum, Bd. 6, Verlag am Goetheanum, Dornach, 1994

Haller L., Heusser P., Treichler M., et al.

Immunologie und Krebskrankheit – Zur Therapie mit Iscador. Beiträge zur Krebs-therapie. Verlag Urachhaus, Stuttgart, 1993

Leroi R. (Hrsg.) Misteltherapie – Eine Antwort auf die Herausforderung Krebs. Die Pioniertat Rudolf Steiners und Ita Wegmans. Verlag Freies Geistesleben, Stuttgart, 1987

The aims of the Society for Cancer Research are

– research in the field of cancer– further development of the medicament

introduced by Rudolf Steiner– further refinement of methods of treatment– providing postgraduate medical training

in those methods.

The registered name of the medicament is Iscador. It is produced from different types of mistletoe (Viscum album).

The Society for Cancer Research does not seek material gain. The charitable nature of the work is recognised by exemption from tax. Streicher & Brotschin Revision und Unternehmensberatung AG in Basel have been appointed auditors.

The Executive Boardof the Society for Cancer Research

Iwer HelwigMichael LorenzMichael Werner

The ideas and opinions expressed in individual articles are those of the authors.

Editing: Corina M. Caminada / Silke Helwig

Print: Schwabe AG, Muttenz

Pictures pp. 9, 42–43: Lukas Klinik archivePictures pp. 46, 59, 62: made available by the writersAll other pictures and postcard: Jürg Buess

Translation: Matthew Barton, GB-Bristol

The Society for Cancer Research

SwitzerlandVerein für KrebsforschungKirschweg 9, CH-4144 ArlesheimPhone +41 61 706 72 72Fax +41 61 706 72 00E-mail: c.brodmann@vfk.chInternet: www.vfk.ch

Donations directly to the Verein für Krebs forschung are accepted as personal or bank cheque. Please mention “Verein für Krebsforschung” on the memo line.

USARudolf Steiner Foundation, Medical Fund1002A O’Reilley Avenue, San Francisco, CA 94129-0915

Donation to the Foundation subject to income tax rebate.

Payment details

To order further issues of our Report or address change please contact:

Verein für KrebsforschungAttn. of Ms. Christine BrodmannKirschweg 9CH-4144 Arlesheimc.brodmann@vfk.ch

Information on Lukas Klinik:www.lukasklinik.chE-mail: kontakt@lukasklinik.chInfoline: +41(0)61 702 09 09Mo 17.00–20.00Wed 08.00–14.00Fri 14.00–17.00

Report2013

Verein fürKrebsforschung

ArlesheimSwitzerland

Lukas KlinikInstitut Hiscia